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Introduction 
Parenteral therapies  
In recent decades medicine and pharmacy have had to face many new challenges. Not only 
the need to treat cancer [1,2] encouraged innovation, but also the need to develop therapies for 
widespread diseases, such as diabetes mellitus [3] or numerous cardiac diseases [4] have 
called for enormous progresses. To give an impression of the extent of the issue, the 
incidences of selected solid tumors in the US, estimated for the year 2000 and 2004 by the 
American Cancer Society, are depicted representatively in Table 1. 
Table 1: Incidences of selected solid tumors in the US in the years 2000 and 2004 (source: American cancer 
society). 
Number of new cases Number of deaths 
Type of cancer 
2000 2004 2000 2004 
Breast 182,800 217,440 41,200 40,580 
Prostate 180,400 230,110 31,900 29,900 
Lung 164,100 173,770 156,900 160,440 
Colon 93,800 106,370 47,700 56,730 
Rectum 36,400 40,570 8,600 N/A 
Pancreas 28,300 31,860 28,200 31,270 
Ovary 23,100 25,580 14,000 16,090 
Brain & other nervous 
system N/A 18,400 N/A 12,690 
 
These data show the tremendous increase in the newly occurring cases of cancer and the 
limited chances for healing lung and brain cancer. But Table 1 also shows that the number of 
cancer deaths increased less rapidly or in some cases even decreased from the year 2000 until 
present. In the field of pharmaceutical science, therapies can be approved by the development 
of new drugs and by increasing the efficacy of treatments with existing drugs. But 
consequently, with increasing possibilities in the design of new drugs, the requirements for 
their application have increased tremendously, too. In recent years many sensitive substances, 
above all proteins and peptides, have gained much importance [5,6]. The investigated 
triglyceride matrices can contribute to the treatment of various cancer forms such as for 
example brain cancer [7] and they are one possibility to overcome limitations for the 
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administration of proteins and peptides [8]. Because although the oral application of a protein 
like insulin would be desirable, due to advantages such as easy administration and good 
compliance, this mode of administration would lead to a bioavailability of less than 1-2% 
[5,9]. This is only one example among a plethora of proteins and peptides, which are rapidly 
degraded when administered via the oral route. Likewise, many efforts have been undertaken 
in the field of cancer treatment with various proteins, such as cytokines [10,11], which also 
undergo rapid degradation and can additionally cause severe side effects when administered 
orally. Therefore, the parenteral routes of application have been of increasing interest for 
cancer therapy. 
Parenteral, from para enteron (Greek), meaning “to avoid the intestines”, is generally 
limited to the direct application of drugs into tissues, tissue spaces, vessels or body 
compartments [12], for example by injection, infusion or also implantation, whereby the most 
commonly used routes for the administration of drugs are intravenously (i.v.), intramuscularly 
(i.m.) or subcutaneously (s.c.), depending on the disease to be treated and the desired effects. 
Nevertheless, the definition also includes also several other important ways to apply drugs, 
such as ocularly, nasally and transdermally [12], which represents the exact interpretation of 
the term, meaning all administration principles for drugs, which do not utilize the alimentary 
canal for the delivery of a drug to body tissues. The parenteral application of drugs offers 
several advantages compared to non-parenteral routes. These are, for example, more 
predictable pharmacokinetics and pharmacology and the possibility to quickly interdict a 
rapidly progressing lethal process or disease [12]. Generally, we can distinguish between two 
forms of the treatment. On the one hand, there is the parenteral administration of a drug, for 
example to fight a cardiac arrest by the injection of adrenalin, and on the other hand a long-
term treatment with the goal to treat a disease over an extended period of time. Since the first 
is more often applied in cases of emergency, the long-term therapy becomes much more 
interesting and challenging for pharmaceutical and medical scientists. 
Progress in the parenteral administration of such long-term treatments has already 
contributed to positive developments, for example in the abovementioned successes in cancer 
treatment (Table 1). The triglyceride matrices investigated in this thesis are another possible 
alternative for the long-term administration of medications.  
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Necessity of controlled release 
Parenteral therapies carried out over an extended time period rapidly lose patient 
compliance when drugs have to be administered by direct infusion or injection.  Subsequently, 
the cost of these treatments rises tremendously, due to the need of more highly supervised 
medical care. Therefore, the parenteral controlled release of therapeutic substances over 
longer time periods ranging from a few weeks up to several years is desirable for the 
treatment of many diseases, such as several types of cancer [13-15], diabetes [16], cardiac 
diseases [4], Parkinson’s disease or Alzheimer’s disease [17]. Concomitantly sustained drug 
delivery devices can be used for the treatment of glaucoma [18] or other vitreoretinal diseases 
[19] and for hormonal contraception [20] or hormone substitution [21]. Recent investigations 
also deal with the use of controlled release forms in the field of gene delivery [22-25] for the 
treatment of neurodegenerative diseases. 
Controlled release delivery systems have several advantages, compared to the intermittent 
i.v. or oral drug administrations [6,16,26], such as the maintenance of therapeutic levels of a 
drug and the reduction of negative side effects due to a lower required amount of drug when 
administered locally. Additionally, the number of dosages can be decreased and the delivery 
of drugs with short in vivo half-lives can be facilitated. With regard to the limited ability of 
many drugs, especially proteins, to cross physiological barriers, such as the blood-brain 
barrier (BBB) [6,17] or the inner and outer blood-retinal barriers [19], another important 
advantage for the use of local parenteral drug delivery systems, such as the triglyceride 
matrices investigated for this thesis, becomes obvious. 
 
Drug delivery devices 
In recent decades, tremendous efforts have been undertaken in the field of controlled 
release devices and a plethora of systems have been developed and investigated for their use 
in parenteral drug delivery. Thus, it would be impossible to give a complete overview of drug 
delivery devices; therefore only a brief description of the classes of systems used for 
controlled release and drug delivery follows. 
Generally particulate systems, such as nanoparticles [27-30] (including liposomes [31,32]) 
and microparticles [6,33-35] can be distinguished from macroscopic implantable devices 
[2,7,36,37] in the field as the most important candidates for the design of controlled release 
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systems. In addition, a plethora of new strategies for the controlled parenteral delivery of 
drugs have been investigated, such as in situ gelling systems [38], microchip devices [2,4,39] 
or stents which are able to control the release of drugs [4,40]. 
Nanoparticles and liposomes are already used in several areas of drug delivery and 
cosmetics. They offer the advantage of facilitated specific targeting [41], due to their size, 
which leads to an uptake into cells via phagocytosis [42,43]. Nanoparticles usually are smaller 
than 100nm and thus are not excluded from cells. Small molecules, peptides, proteins and 
nucleic acids can be loaded into nanoparticles that are not recognized by the immune system 
and that can be targeted to particular tissue types. Nonspecific attachment or uptake can be 
reduced by the use of poly(ethylene glycol) (PEG) [44]. Hitherto nanoparticles and liposomes 
have been investigated for their use in cancer therapy [45] or gene delivery [27] and recently 
research involving the nuclear targeting of these small devices has also been carried out [46]. 
Microparticles are also a widely investigated device for drug delivery, due to improved 
abilities for sustained release compared to nanoparticles. Their size can range from one to 
several hundred micrometers, which allows for a larger drug reservoir and thus facilitates a 
more prolonged drug release. One major advantage of microparticles is the possibility to 
suspend and inject them. Microparticles can be administrated to provide localized release of 
therapeutic agents as controlled release devices in several ways. Drug delivery via 
subcutaneous as well as intracranial injection for example has been widely investigated [47-
49]. An appealing aspect of a microparticle-based delivery system is that stereotactic injection 
to a specific region of the brain passes the BBB, thereby enabling prolonged delivery directly 
to the CNS. Efforts have also been undertaken in the fields of inhalative aerosol delivery of 
drugs into deep lung tissue [50,51] and oral insulin delivery [52] by the use of microparticles. 
But despite several advantages such as injectability, facilitated preparation procedure and 
longer drug release periods compared to nanoparticles, the capability of microparticular 
devices for drug incorporation and thus for controlled prolonged release is still limited. 
The third system for parenteral drug delivery, which should be described, is macroscopic 
implants. They have been investigated for many purposes. In 1999, Evans et al. described 
their fabrication into structural supports, which can be used to promote nerve regeneration 
[53], which is also described in other references [54,55]. Their use in the treatment of various 
cancers has been widely investigated [7,13] and a plethora of scientific papers describe their 
use as cell carriers in tissue engineering or cell transplantation [56-60]. A disadvantage of 
three-dimensional macroscopic implants, which can be on the millimeter to centimeter scale, 
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compared to particulate devices, which can be suspended and injected, is the need for surgery 
to administer the device. But due to their size, implants can provide a larger depot of the 
administered drug compared to particulate systems. Their macroscopic size also facilitate the 
incorporation of larger proteins, which is limited for example in case of nanoparticular 
systems. Additionally, implantable devices are easier to prepare and allow for a variation in 
their geometries like size, shape and porosity, which can be tailored to the application. 
Thus, implants can be considered to be one of the most important candidates for controlled 
release drug delivery over an extended period of time like several months. 
 
Non-degradable and bioerodable drug delivery systems 
Many materials have been investigated for applications in drug delivery devices. The first 
controlled release systems were based on non-degradable synthetic polymeric materials, 
principally silicone elastomers. In 1964, Folkman et al. noticed the penetration of certain dye 
molecules through the wall of silicone tubing [61,62]. This observation lead to the 
development of so called reservoir drug delivery systems, which are hollow tubes filled with a 
drug suspension or compact drug cores surrounded by permeable non-degradable membrane. 
The device properties, such as thickness and permeability of the tubing or membrane, 
respectively, control the release rate of the drug [2]. This principle is used for example in the 
Norplant® contraceptive delivery system and was tested for carmustine delivery from silicone-
encased drug reservoirs in cancer treatment [16,63]. Two advantages of such systems are the 
variability of membrane materials, which allows for exact adjustment of the desired release 
profile and the possibility to achieve zero order drug release kinetics comparable to i.v. 
injection. The major disadvantage of the reservoir principle is the danger of the so-called dose 
dumping when a mechanical defect in the membrane of the system occurs and the whole drug 
is released rather abruptly. This may cause severe or even lethal side effects. 
The second type of non-degradable implantable controlled release device is represented by 
the matrix system, within which the drug is homogenously dispersed. Thus, these devices are 
simpler and potentially safer compared to the reservoir type systems. Controlled release from 
matrix devices occurs by diffusion of the substances throughout the matrix. An example for 
this kind of release system is the Cypher coronary stent®.  
 Figure 1 depicts the mechanisms of drug release from reservoir and matrix type of non-
degradable drug delivery systems. 
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Figure 1:  Mechanisms of drug release from non-degradable drug delivery systems  
a) diffusion controlled reservoir systems, a core is surrounded by a non-degradable membrane 
b) matrix system, drug is embedded homogenously into the matrix material, release can be 
controlled by diffusion, erosion or both. 
Both reservoir and matrix systems require minor surgery to implant as well as to remove 
the devices. This disadvantage of invasive procedures when administering non-degradable 
drug delivery systems is less pronounced in veterinary medicine, where the removal of 
subdural implants is not necessary. Thus implants for the controlled release delivery of 
estradiol to improve the growth rate and feed uptake in cattle were developed by Lilly 
research laboratories [64,65]. 
Another example for non-degradable drug delivery system, which was used in the 1990ies 
for the treatment of osteomyelitis, is a device containing gentamycin embedded into a matrix 
of poly(methylmethacrylate) (PMMA, also called “bone cement”) [66-70]. Investigations 
carried out by Wahling et al. using gentamycin-loaded PMMA beads revealed much higher 
local antibiotic concentrations than can be safely achieved with the usual parenteral 
administration techniques [71,72]. Also in 1992 Dash and Suryanarayanan investigated this 
means of treatment for bone infection by using tobramycin embedded in 
poly(dimethylsiloxane) (PDMS) [73]. The major advantage of this device is the locally 
targeted therapy directly at the site of infection. However, the underlying disadvantage of this 
delivery system is the necessity for surgical removal of the implant after the therapy is 
completed and thus therapy of the exemplified indication has changed in the recent years. 
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Degradable macroscopic drug delivery systems 
The fact that all non-degradable drug delivery systems have to be removed surgically is 
obviously the most important limitation these devices. This both reduces patient compliance 
and also makes therapy more difficult. Thus, in recent decades, biodegradable systems have 
gained much popularity over non-degradable delivery devices [74,75]. Biodegradability of an 
administered material means the capability to be degraded and eliminated by the body within 
a certain time period. The major advantage of biodegradable drug delivery systems is that the 
inert materials used for the fabrication of the devices are eventually absorbed or excreted by 
the body. This alleviates the need for surgical removal of the implanted system after the 
completion of the therapy, thereby increasing patient acceptance and compliance [76]. 
Biodegradable materials can be used for the preparation nearly every drug delivery system, 
including for example nanoparticles, liposomes, microparticles, micelles and macroscopic 
implants. Biodegradable drug delivery devices which are already commercially available are 
for example Lupron Depot® [77], Decapeptyl® [78] and Zoladex® [79] all used for the 
treatment of prostate cancer and Nutropin Depot® which is employed in the growth failure 
therapy [6]. All these devices are based on poly((D,L-lactic-co-glycolic acid) (PLGA) in 
contrast to Gliadel® [80], which is based on poly(bis(p-carboxyphenoxy)propane) - sebacic 
acid (pCPP-SA), representing a further biodegradable material for the preparation of 
parenteral drug delivery devices. However, the design of a biodegradable drug delivery 
system is not easy, due to many factors, which can influence the degradation rate and thus 
play important roles for the resulting release profile, especially when using polymeric 
materials. Alterations in pH of body compartments or body temperature as well as changes in 
the surface area or shape of the device have to be considered in the design of a biodegradable 
drug delivery system [81]. Another problem that occurs with bioerodable controlled release 
devices is the slow diffusion of the drug from the matrix [76] which becomes a major 
challenge to overcome when developing biodegradable systems whose use is intended for 
extended release applications or situations in which the drug has a narrow therapeutic index 
[16]. One of the key factors in the design of a biodegradable controlled release drug delivery 
system seems to be the chosen matrix material. 
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Materials 
Hitherto most investigations on drug delivery have been carried out on polymers and all 
commercially available controlled release devices for parenteral administration utilize 
polymers to obtain a sustained liberation of the drugs [2,6,16,20]. Table 2 gives a partial 
overview of the commercially available sustained release devices and the used materials 
[6,13,82-84], which are all synthetic polymers and whose biocompatibility is widely accepted. 
Table 2: Partial overview of commercially available drug delivery systems and the used materials. 
Product name Material Drug released Application 
Cypher coronary 
stent® 
Ethylvinylacetate 
copolymer 
EVAc + PBMA 
sirolimus coronary artery disease 
Decapeptyl® 
poly(D,L-lactic-co-
glycolic acid) 
PLGA 
(D-Trp6)LH-RH prostate cancer 
Gliadel® pCPP-SA carmustine glioblastoma 
multiforme 
Lupron Depot® poly(D,L-lactic acid) PLA leuprorelin acetate 
prostate cancer, 
endometriosis 
Jadelle® dimethylsiloxane/ 
methylvinylsiloxane levonorgestrol contraception 
Norplant® silastic rubber levonorgestrol contraception 
Nutropin Depot® 
poly(D,L-lactic-co-
glycolic acid) 
PLGA 
human growth hormone growth failure 
Septopal® poly(methylmethacrylate) PMMA gentamycin sulfate osteomyelitis 
Taxus coronary 
stent® translute
a
 paclitaxel coronary artery disease 
Trelstar Depot® 
poly(D,L-lactic-co-
glycolic acid) 
PLGA 
triptorelin pamoate prostate cancer 
Zoladex® 
poly(D,L-lactic-co-
glycolic acid) 
PLGA 
goserelin acetate prostate cancer, 
endometriosis 
aA Boston Scientific proprietary non-degradable polymer 
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Since the number of materials investigated for the manufacture of controlled release drug 
delivery devices is tremendous, only a partial overview of materials is depicted in Table 3. 
The materials are devided into synthetic and natural polymers, natural hydrogels and lipid 
materials. 
Table 3: Materials investigated for their use in the design of biodegradable controlled release drug delivery 
systems. 
synthetic polymers natural polymers hydrogels lipid materials 
ABA triblock copolymers 
[135] albumin [106-110] 
alginates 
[120,121] cholesterol [35,127] 
Ethylvinylacetate 
copolymer (EVAc) [136] cellulose [83] collagen[6] 
dipalmitoyl-
phosphatidyl-choline 
[126] 
hydroxyapatite [137] chitosan / chitin [113] fibrin [118,119] 
fatty acid anhydrides 
[142] 
poly(ortho esters) [17] chondroitin sulfate [116,117] gelatin [82,111] fatty acids [128,142] 
polyamides [138] hyaluronic acid [114]  Gelucire
®, 1 [143] 
polyanhydrides [6,38,138] starch [102-105]  hydrogenated castor 
oil [144] 
poly(ε-caprolactone) [139]   lecithin [145] 
polycarbamates [138]   monoglycerides [146] 
polycarbonates [138]   triglycerides [34,35,131] 
poly(glycolic acid) (PGA) 
[141]   waxes [129] 
poly(D,L-lactic-co-
glycolic acid) (PLGA) 
[140] 
   
poly(lactid acid) (PLA) 
[63]    
polyphosphazene [138]    
polyurethanes [138]    
silicone [6]    
1
 Gelucire® is a mixture of glycerides and fatty acid esters. 
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In addition to polymers used in the commercially available drug delivery systems a 
plethora of polymeric materials and structures are available and numerous groups are 
currently carrying out experiments on cancer treatments using these materials for the design 
of controlled release devices. The delivery of hormones [122-124], cytokines [104], and non-
protein anticancer drugs, such as 5-Fluorouridine [95], Cisplatin [125,126] or Doxorubicin 
[127-130] from polymeric systems has been investigated for cancer therapy. Concomitantly, 
polymeric materials are investigated for their use in the treatment of neurodegenerative 
diseases, such as Parkinson’s and Alzheimer’s disease [17] and for future therapy of diabetes 
mellitus [3] and various cardiovascular diseases [131-134]. 
For their suitability as material for the preparation of parenteral controlled release drug 
delivery systems, synthetic polymers display some advantages, such as variable release 
properties, well-defined degradation pathways [135] and acceptable in vivo biocompatibility 
[136-138]. However polymeric materials also show several disadvantages, especially as the 
delivery of proteins proves to be a more challenging task for pharmaceutical scientists. High 
shear forces, heating, exposure to organic solvents [139], interface formation [140], as well as 
the chemical microenvironment inside eroding polymers with acidic pH [141], increased 
osmotic pressure [135] and acylating degradation products [142] often result in irreversible 
changes in protein structure and activity [139]. Therefore, alternative materials to 
biodegradable synthetic polymers that avoid these stress factors may become increasingly 
important for the delivery of protein and peptide drugs in the near future. 
For this purpose, several natural materials were investigated. Early examples with natural 
polymers are controlled release experiments of Mitomycin C, 5-Fluorouracil and 5-
Fluorouridine from starch microspheres [110-113] carried out in the eighties and nineties by a 
few groups. Also albumin [86-90] and gelatine [104,105] microspheres were investigated in 
the field of controlled release for cancer treatment. Further studies were carried out on 
chitosan [98,143], hyaluronic acid [108], cellulose [95], ethylcellulose [144] and chondroitin 
sulfate [102,103], all representing natural biodegradable polymeric materials for the 
controlled release of drugs. By the use of natural polymers for controlled release, most of the 
abovementioned disadvantages of the synthetic polymers, especially the stress factors to 
which the incorporated drugs are exposed, can be alleviated and their biocompatibility is also 
widely accepted. However, there might be difficulties in the design of the desired release 
profile or degradation time, due to structural limitations. 
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A second group of alternative materials to the synthetic polymers for the preparation of 
parenteral delivery systems, generally also being natural polymers, are natural hydrogel-
forming agents. Potential candidates, which are currently investigated are fibrin [99,100], 
alginates [91,92], carboxymethylcellulose [145-147], gelatine [104,105] or collagen [6,148]. 
Natural hydrogels have the advantage that they can protect proteins and peptides from 
degradation [6], which makes them promising candidates for the use as carrier materials in the 
field of controlled release. 
As a third group, lipid materials might be a promising alternative to synthetic polymers for 
the design of controlled release drug delivery devices, whereby several substances were 
investigated for their potential in this field. Among these physiologically existing materials, 
which also include cholesterol [37], phospholipids [96], lecithin [93], fatty acids 106] and 
waxes [120], all forms of glycerides with fatty acids of variable chain lengths are of great 
importance [29,36,37,149,150]. Lipid materials show high variability of available structures, 
and thus allow for the design of many desired release profiles. Concomitantly, the mentioned 
negative stress factors for polymeric materials can be avoided and, as physiologically 
occurring substances, these materials should prove to be biocompatible. This makes lipid 
materials a promising candidate as an alternative material to the synthetic polymers for the 
design of controlled release parenteral drug delivery systems. 
Triglycerides as one representative for the lipid materials showed promising controlled 
release properties [36,37] and their use for the preparation of microspheres [118] and solid 
lipid nanoparticles (SLN) [151,152] have shown good results for the incorporation of 
proteins. Thus with regard to a long-term administration of proteins, developing triglyceride 
implants that allow for a more prolonged release period [36,37] and higher drug dosages, due 
to their macroscopic size, may be of great interest for researchers in this field. 
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Goals of the thesis 
Compared to synthetic polymers, the use of triglycerides avoids the abovementioned stress 
factors for the incorporated drug, such as the microenvironment within eroding polymeric 
implants with increased pH and osmotic pressure, acylating degradation products, which often 
irreversibly changes the structure and activity of incorporated proteins or peptides. In 
addition, triglycerides show structural variability, which facilitates the design of a controlled 
release system with a desired release profile. As physiologically occurring material, the 
biocompatibility of triglycerides is likely.  
The general goal of this thesis was the investigation of triglycerides as materials for the 
preparation of parenteral controlled release matrices. The main intentions were to characterise 
the material to facilitate the design and preparation of controlled release matrices and to 
ensured the in vivo safety of the material. 
Due to their promising properties, triglycerides are currently being investigated for their 
use as carrier material for proteins and peptides [36,37,153,154]. To facilitate investigations 
on the stability of proteins and peptides within the matrix, an extraction method for the 
recovery of the incorporated drugs was the first aim of this thesis (chapter 3). Insulin and 
somatostatin served as model drugs for the development, optimization and evaluation of the 
procedure. 
Many basic factors concerning the preparation procedure for triglyceride matrices and their 
release properties as well as the biocompatibility and in vivo erosion of the triglyceride 
matrices are of great importance for the design of cylindrical triglyceride matrices, 
necessitating the mechanistic studies that were carried out and described in this thesis. 
The investigations presented in chapter 4 served to evaluate the preparation of the 
cylindrical triglyceride matrices, to identify crucial parameters during the manufacturing 
procedure and to quantify their influence on the resulting release profiles. Concomitantly, 
basic release properties of the triglycerides were characterized and release mechanisms from 
the material identified. To this end, fluorescence dyes were used as model drugs. 
After the preparation procedure for cylindrical triglyceride matrices was evaluated and 
basic release properties of the material were investigated, in chapter 5 the in vivo 
biocompatibility of triglycerides, which is the most essential prerequisite for a biomaterial to 
prove suitability for the preparation of drug delivery systems for the parenteral administration, 
was examined. Additionally, in vivo erosion and stability of lipid matrices was of special 
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interest in this part of the thesis, representing another important requirement for controlled 
release of drugs in vivo. 
Subsequent to the determination of long term in vivo stability of triglyceride matrices in 
chapter 5, possibilities to accelerate triglyceride erosion is described in chapters 6 and 7. 
First, the use of several excipients as modifiers in the erosion of triglyceride matrices was 
examined in vitro in chapter 6. The goal of this study was to decrease the matrix stability and 
thus accelerate the erosion but to maintain the prolonged release properties of the triglyceride 
material. The influence of the excipients on the release from triglyceride matrices was 
characterized and their suitability for prolonged in vitro release over several weeks was 
investigated. Consequently, the hypothesis for the use of hydrophilic erosion modifiers and 
the dependence of the in vivo erosion on the triglyceride particle size was then investigated in 
chapter 7. 
As one possible application for lipid implants as controlled release drug delivery systems, 
programmable implants containing a drug-loaded triglyceride core embedded into a drug-free 
bulk-eroding polymer mantle were also investigated (chapter 8). These devices were first 
described by Vogelhuber et al. [39], but only allowed for pulsatile release, because of a 
polyanhydride core. It was thus important to demonstrate the viability of prolonged drug 
liberation from programmable implants having a triglyceride core. Last, but not least, 
convolution theory was investigated for its suitability to predict release profiles from 
programmable implants showing the controlled release of the drug from the core material. 
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Chapter 2 
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1 Materials 
1.1 Matrix materials  
The triglycerides for matrix preparation were purchased from Sasol GmbH, Witten, 
Germany. Materials included glyceroltrilaurate (Dynasan® 112), glyceroltrimyristate 
(Dynasan® 114), glyceroltripalmitate (Dynasan® 116) and glyceroltristearate (Dynasan® 118). 
Cholesterol and gelatin, which served as further matrix materials were obtained from Sigma-
Aldrich (Deisenhofen, Germany). Polymeric matrices were made from polylactic-glycolic 
acid (PLGA) and polylactic acid (PLA) of varying molecular weights. The PLGAs Resomer® 
RG502H (50/50, Mw = 10,500, PLGA10) and Resomer® RG502 (50/50, Mw = 17,000, 
PLGA17) as well as the PLA Resomer® R503 (Mw = 30,000, PLA30) were kindly provided by 
Boehringer Ingelheim (Ingelheim, Germany). 
 
1.2 Excipients for the matrix manufacture 
Experiments on the biocompatibility and erosion behavior of the lipid materials were 
carried out using the phospholipids dimyristyl-phosphatidyl-choline (DMPC), dipalmitoyl-
phosphatidyl-choline (DPPC) and distearoyl-phosphatidyl-choline (DSPC). All phospholipids 
were kindly provided by Lipoid GmbH (Friedrichshafen, Germany). Sucrose (Südzucker, 
Regensburg, Germany) and agarose (Fluka/Sigma-Aldrich, Deisenhofen, Germany) were used 
as further excipients for the matrix preparation. 
 
1.3 Model drugs 
Bovine insulin used for extraction analysis was a gift from Hoechst (Frankfurt, Germany) 
and somatostatin was kindly provided by Dr. Wilmar Schwabe Pharmaceuticals (Karlsruhe, 
Germany). For release experiments, the fluorescent dyes pyranine, fluorescein-di-sodium salt 
and nile red (all Sigma-Aldrich, Deisenhofen, Germany) served as model drugs. 
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1.4 Chemicals 
All reagents used were analytical grade or better. Water used for the experiments was 
double-distilled and filtered through a 0.2µm cellulose nitrate filter (Sartorius, Göttingen, 
Germany) prior to use. Tetrahydrofuran (THF), methylene chloride, chloroform and ethanol 
were obtained from Merck (Darmstadt, Germany) and acetonitrile was purchased from 
Mallinckrodt Baker B. V. (Deventer, Netherlands). Trifluoroacetic acid (TFA) was obtained 
from Sigma-Aldrich (Deisenhofen, Germany). Silicon oil was purchased from Carl Roth 
GmbH & Co. (Karlsruhe, Germany). Tissue Tek for cryo-sectioning was obtained from 
Sakura Finetek (Torrane, CA, USA). Sodium azide, which was purchased from Sigma-
Aldrich (Deisenhofen, Germany), was added to release buffers as a preservative. 
 
1.5 Animals 
All in vivo studies were carried out with female immunocompetent NMRI-mice, which 
were purchased from Charles River Deutschland GmbH (Sulzfeld, Germany). 
 
1.6 Instruments 
Used substances were weighed on a Mettler Toledo AT261 analytical scale (Mettler 
Toledo, Giessen, Germany) or an electronic Sartorius 4401 micro-balance (Sartorius, 
Göttingen, Germany). Matrix preparation was carried out using a self-made manual 
compression tool made of hardened steel (machine shop, University of Regensburg, 
Germany) and a hydraulic press (Perkin Elmer, Rodgau-Jügesheim, Germany). For 
thermographic analysis a DSC 2920 differential scanning calorimeter (TA Instruments, 
Alzenau, Germany) was used. 
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2 Methods 
2.1 HPLC-Analysis of Insulin and somatostatin 
HPLC analysis was performed for insulin and somatostatin using a system with a Degasser 
(Knauer, Berlin, Germany), LC-10AT pump, FCV-10ATVP gradient mixer, SIL-10ADVP 
autosampler, CTO-6A column oven, SPD-10AV UV-detector, RF-551 fluorescence detector 
and SCL-10AVP controller (all Shimadzu, Duisburg, Germany). For somatostatin, a linear 
gradient from 26% to 39% acetonitrile in water, with 0.1% trifluoroacetic acid (TFA), as 
mobile phase was applied over 15 minutes at a flow rate of 1.0ml/min. 100µl of the samples 
were separated at a temperature of 40°C using a combination of a C18-reversed phase pre-
column (LC318, 4.6mm x 5.0mm) and an C18-reversed phase analytical column from 
Supelco (Deisenhofen, Germany). Chromatograms were detected at 210nm and 274nm, 
respectively by UV detection and at wavelengths of 274nm / 308nm (excitation/emission) for 
the fluorescence detector. 
The procedure for insulin differed from that for somatostatin only in the duration of the 
linear gradient. Here the concentration of acetonitrile in water (+0.1% TFA) was constantly 
increased from 26% to 39% over a period of 24 minutes. Again 100µl-samples were separated 
at 40°C using the above-mentioned combination of pre-column and analytical column. 
Chromatograms were detected by UV and fluorescence detection as described above. Both 
analytical methods were linear and reproducible in concentration ranges from 4µg/ml to 
150µg/ml. 
 
2.2 Stability test of somatostatin and insulin in release medium 
To investigate whether the release of the model drugs from triglyceride devices could be 
determined directly from the release medium, investigations into the stability of insulin and 
somatostatin were carried out in isotonic phosphate buffer at pH 7.4. To this end, the 
substances were dissolved in 1.0ml HPLC-vials to a concentration of 150µg/ml. Afterwards 
the solutions were incubated at 37°C in a Memmert U40 drying oven (Memmert, Schwabach, 
Germany). Drawn samples were immediately frozen at -80°C and quantitatively analyzed 
together per HPLC after the incubation time of 5 weeks was completed.  
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2.3 LC/MS-Analysis of insulin and somatostatin 
To clarify the degradation pathways of the model drugs during the incubation in release 
medium, insulin and somatostatin samples from the stability experiments underwent LC/MS-
analysis, which was performed to identify the separated substances. The chromatographic 
conditions were transferred to a Hewlett-Packard HPLC-system with series 1100 degasser, 
binary pump, autosampler, column oven and diode array detector (all Hewlett-Packard, 
Waldbronn, Germany), coupled with a TSQ7000 electro-spray-mass spectrometer 
(ThermoQuest, San José, CA, USA) with AP12-source (capillary temperature: 350°C, spray 
voltage: 4.5kV). Substances were detected in total ion chromatograms of the mass 
spectrometer and characterized by analysis of their individual mass spectra.  
 
2.4 Preparation of insulin- and somatostatin-loaded matrices 
For evaluation of the extraction method, which facilitates the recovery of the incorporated 
model drugs from the triglyceride matrix and further investigations on drug stability within 
the matrix, insulin and somatostatin were incorporated into glyceroltripalmitate matrices by 
mixing the two powders. The respective model drug and the triglyceride were both sieved to 
isolate particles 106µm or smaller prior to the mixing step. The mixture was subsequently 
compressed for 10 seconds with a compression force of approximately 250N, using the 
manual compression tool, which is shown in Figure 2, and the described hydraulic press. The 
resulting cylinders had a diameter of two millimeters and a weight of 6.0 ±0.5mg. 
 5 cm
   
Figure 2: Left:  Manual press for matrix manufacture  
right: Schematic of the compression molding.  
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2.5 Extraction methods for insulin and somatostatin 
An extraction method previously described by Lucke et al. [141] was applied and 
afterwards optimized for insulin and somatostatin. In the original method, the sample was 
weighed into a 1.5ml micro test tube (Eppendorf, Hamburg, Germany) and dissolved in 600µl 
of chloroform. For somatostatin, 600µl of an acetonitrile/water/TFA-mixture 
(67.35/32.65/0.1) were added, whereas in the case of insulin either 600µl of 0.01N HCL or of 
an acetonitrile/water/TFA-mixture (29.85/70.15/0.1) were added. The solvent mixtures in 
both cases corresponded to the mobile phase at the elution time point during HPLC-analysis, 
which assured the best solubility of the respective drug. After mixing at 2,200rpm on a Reax 
Control (Heidolph, Schwabach, Germany), the dispersion was allowed to settle at room 
temperature for 10 minutes before the chloroform-phase was finally separated from the 
mixture by centrifugation at 13,200rpm for 5 minutes (Centrifuge 5415 R, Eppendorf, 
Hamburg, Germany). The upper fraction was then used for further analysis. 
To optimize the extraction of the model drugs from glyceroltripalmitate matrices, 
cyclohexane, tetrahydrofuran (THF), toluene and xylene were tested. First, one rod was 
weighed exactly into a 1.5ml micro test tube. Afterwards, 500µl of the respective solvent 
were added and, when needed, was warmed at 35°C in a water bath until the lipid was 
dissolved. The mixture was then centrifuged at 13,200rpm to achieve sedimentation of the 
respective model drug and 450µl of the upper fraction were withdrawn. Subsequently, two 
washing and centrifugation steps with 450µl THF were performed to dissolve and remove the 
lipid completely. After the third withdrawal of 450µl of the washing solution, the samples 
were dried over night under vacuum using a RV5 two-stage oil pump from Edwards 
(Crawley, Sussex, UK). The remaining drug was then dissolved in 1000µl of the 
aforementioned, acetonitrile/water/TFA-mixture to determine its content via HPLC-analysis.
  
 
2.6 Preparation of pyranine-loaded triglyceride matrices 
For the investigation of preparation parameters that influence the release from the resulting 
pyranine-loaded triglyceride matrices, cylinders containing the hydrophilic fluorescent dye as 
a model drug were prepared under varying conditions. To this end, the respective amount of 
glyceroltripalmitate was dissolved in tetrahydrofuran and mixed with a solution of the needed 
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amount of the dye in water. The ratios of triglyceride and pyranine used varied with the drug 
loading, whereby a total 200.0mg of dye-loaded triglyceride was dissolved. The resulting 
mixture with a THF/water-ratio of 9:1 was frozen in liquid nitrogen and subsequently freeze-
dried, using the two-stage oil pump mentioned above (see section 2.5). Afterwards, the 
obtained powder was ground and mixed in a mortar and then compressed to cylindrical 
matrices of 1mm or 2mm diameter, as described in section 2.4. 
Drug loading was varied from 1% over 10% up to 33% pyranine. These matrices were 
compressed with a force of 250N. Additionally, matrices containing 10% pyranine were 
prepared by applying a compression force of 50N and 500N. Cylindrical matrices with a dye 
content of 10%, diameters of 1mm and 2mm and heights of 2mm, 4mm and 6mm were 
compressed by applying a force of 250N. In addition, glyceroltripalmitate was sieved to 
fractions of particle sizes below 106µm and 106µm-250µm and subsequently mixed with the 
dye to a total pyranine content of 10%. Afterwards, this powder mixture was compressed to 
cylinders of 2mm diameter as described above. 
For experiments on the effects of drug hydrophilicity, fluorescein-di-sodium salt and nile 
red served as model drugs in cylinders of 2mm diameter and a dye loading of 10%. Matrix 
manufacture with fluorescein was performed using the above-described procedure for 
pyranine. For the incorporation of nile red into the matrices, both the dye and the triglyceride 
were dissolved in THF and afterwards this solution also underwent the above-mentioned 
process for manufacture of matrices. 
10% fluorescein-di-sodium salt containing matrices for the investigation of involvement of 
osmosis in release mechanisms from triglyceride cylinders were prepared as described above. 
For the investigation of the water uptake into triglyceride matrices, glyceroltripalmitate 
was sieved to fractions of particle sizes below 106µm and 106µm-250µm and subsequently 
compressed to cylinders of 2mm diameter as described above. 
 
2.7 Solubility of nile red in release medium 
To be able to draw conclusions from release experiments performed with the highly 
lipophilic florescent dye nile red, which was used as model drug for the investigation of the 
influence of drug characteristics on the resulting release profile from a triglyceride matrix, the 
solubility of the dye in the release medium was determined. To this end, 0.2mg nile red were 
weighed into 20ml of phosphate buffer pH 7.4 and subsequently incubated for 2 days at 37°C 
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in the aforementioned heating oven. After centrifugation of the mixture, 5.0ml of the upper 
fraction were taken for the following procedure. Solubility data were obtained by measuring 
fluorescence of the samples after freeze-drying and re-dissolution of the remaining solid 
phase in ethanol. A RF-1501 fluorescence spectrophotometer (Shimadzu, Duisburg, Germany, 
λex/λem: 567nm/629nm) was used for the measurements. 
 
2.8 In vitro release set-ups 
2.8.1 Release of pyranine 
To investigate the influence of preparation parameters on the release from triglyceride 
matrices, experiments were carried out using pyranine as model drug. For investigation of the 
in vitro release of pyranine-loaded matrices, the samples were incubated at 37°C in 50ml 
0.1M phosphate buffer solution (pH 7.4) while subjected to gentle shaking in a GFL 1086 
horizontal shaking water bath (GFL, Burgwedel, Germany). To suppress the growth of 
bacteria and fungi, 0.05% sodium azide were added. The withdrawn volume of the samples 
was replaced by fresh buffer solution and the pyranine content of the samples was measured 
using the aforementioned fluorescence spectrophotometer (λex: 403nm, λem: 503nm). 
 
2.8.2 Release of fluorescein and nile red 
To examine the influence of dye hydrophilicity, fluorescein and nile red were used as 
model drugs. Fluorescein properties were varied by incubation in buffers having pH values of 
2.8, 5.5, and 9.0, respectively. Again a temperature of 37°C was chosen and 0.05% sodium 
azide was added as a preservative. Fluorescein release from the matrices was investigated by 
measuring fluorescence in phosphate buffer with pH 9.0 using excitation/emission 
wavelengths of 491nm/505nm; samples were collected as described in section 2.8.1 for 
pyranine. Concomitantly, matrices containing the highly lipophilic fluorescent dye nile red 
were incubated as mentioned in section 2.8.1 for pyranine. Release data from nile red-loaded 
lipid cylinders were obtained by measuring fluorescence after freeze-drying of the completely 
exchanged release medium at the specific time points and re-dissolution of the remaining 
solid phase in ethanol (λex/λem: 567nm/629nm). 
 
Chapter 2  Materials and Methods 
 -29-  
2.8.3 Investigation of release mechanisms 
To investigate by an in vitro release experiment whether osmosis is involved in release 
mechanisms from triglyceride matrices, 10% fluorescein-di-sodium salt loaded 
glyceroltripalmitate cylinders were incubated in phosphate buffer solutions (pH 9.0) having 
three different osmotic pressures. Sodium chloride was added to the phosphate buffer to 
achieve osmotic pressures of 293, 7850 and 9500mosmol, respectively. Release data were 
obtained by measuring fluorescence of the dye as described in section 2.8.2. 
 
2.9 In vitro investigation of water uptake into triglyceride matrices 
To further investigate the release mechanisms from triglyceride matrices, their water 
uptake was examined as follows. For the investigation of the water uptake into 
glyceroltripalmitate cylinders, the blank rods were incubated for up to 14 days in phosphate 
buffer containing 30mg/ml fluorescein-di-sodium salt at a pH of 9.0 and a temperature of 
37°C. After the withdrawal of the matrices, they were washed with 3.0ml of double distilled 
water. The dye was subsequently extracted according to the method described by  Lucke et al. 
[141] (see section 2.5) using 1.0ml of chloroform and of the mentioned phosphate buffer as 
solvents. Afterwards the fluorescein content was measured as described above and the relative 
amount of water taken up by the cylinder was calculated. 
 
2.10 Cryo-sectioning of matrices 
After incubation of the blank cylinders in phosphate buffer containing fluorescein-di-
sodium salt, additionally the distribution of the dye solution within the matrices was 
investigated. To this end, a cross-section of the triglyceride cylinders was made using a HM 
550 OMP cryotome from Microm International (Walldorf/Baden, Germany). A chamber 
temperature of -10°C and a sample temperature of 5°C were applied. Afterwards, 
approximately one half of the matrices were cut away in slices of 20µm each. To this end the 
cylinders were embedded on cryo-stubs (Microm International, Walldorf/Baden, Germany) in 
tissue tek within a ring having a diameter of approximately 1.5cm and a height of 
approximately 0.75cm. Tissue tek was removed before microscopic investigation of the 
remaining half of the matrix by using a soft paper tissue. 
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2.11 Confocal Laser Scanning Microscopy 
Subsequent to the cross-sectioning of the matrices, they were investigated by fluorescence 
microscopy using an Axiovert 200M confocal laser-scanning microscope with LSM510 laser 
module (both Carl Zeiss, Jena, Germany). For the detection of fluorescein-di-sodium salt 
(λex/λem: 491nm/505nm) the laser with an excitation wavelength of 488nm was chosen and 
emission was detected at wavelengths above 505nm. No further filters were used. 
 
2.12 Preparation of sterile matrix materials for in vivo studies 
After the in vitro characterization, the triglyceride matrices were tested for their in vivo 
biocompatibility and erosion. To evaluate tissue reactions, sterile materials had to be used in 
order to avoid reactions not related to the material. The phospholipid distearoyl-phosphatidyl-
choline (DSPC) was produced under aseptic conditions by the manufacturer and therefore 
underwent no additional sterilization procedure. 
 
2.12.1 Sterilization of glyceroltripalmitate 
Glyceroltripalmitate was sterilized for 2h at 160°C in a Memmert U40 drying oven 
(Memmert, Schwabach, Germany) and afterwards tempered at 55°C for three days to obtain 
the stable β-modification [8]. 
 
2.12.2 Sterilization of gelatin and poly(D,L-lactic-co-glycolic acid) (PLGA17) 
Gelatin was dissolved in double-distilled water to a concentration of 0.1% and 
subsequently filtered through a PES membrane filter with 0.2µm pore size (Corning, New 
York, USA). Afterwards the solution was freeze-dried using the aforementioned two-stage oil 
pump and subsequent to the drying step the resulting powder was ground in a porcelain 
mortar (Rosenthal, Selb, Germany) under liquid nitrogen. Then the gelatin as well as the 
untreated PLGA17 (Mw: 17,000) was sterilized by UV irradiation for two hours [155]. 
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2.12.3 Sterilization of cholesterol 
Cholesterol used for the matrix preparation for in vivo experiments was first dissolved in 
diethyl ether. Subsequently, the solution was filtered through a PES membrane filter with 
0.2µm pore size (Corning, New York, USA) and then dried under vacuum at room 
temperature in a vacuum desiccator, which was sterilized before for 2h at 160°C in the 
aforementioned heating oven. 
 
2.13 Preparation of sterile matrices for in vivo studies 
For the in vivo studies, cylindrical matrices were compressed from the obtained sterile 
powders. All matrices were manufactured under laminar air flow (UVF 6.12 S, BDK Luft- 
und Reinraumtechnik GmbH, Sonnenbuehl-Gengkingen, Germany) to avoid bacterial 
contamination using the manual press, which is shown in Figure 2 (see section 2.4) and which 
had undergone a heat sterilization process at 160°C for 2 hours. The resulting matrices had a 
diameter of two millimeters and a weight of 6.0 ±0.5mg. A compression force of 
approximately 250N was applied. The sterility of the obtained matrices was tested, according 
to the Ph. Eur., and confirmed in the institute of microbiology at the medical center of the 
University of Regensburg.  
 
2.14 In vivo studies with matrices 
For the investigation of the in vivo biocompatibility and erosion of the lipid materials, two 
in vivo studies were carried out with female NMRI mice (8 weeks old at the beginning of the 
experiment, Charles River Deutschland GmbH (Sulzfeld, Germany)), which were both 
authorized throughout an accepted petition for animal studies. In the first study, two control 
groups of mice received matrices made of gelatin and the aforementioned PLGA17, which are 
accepted to be biocompatible. The two test groups received matrices made of pure 
glyceroltripalmitate and of glyceroltripalmitate containing 1% gelatin (see Table 4). After 
anesthetization with a combination of 100mg/kg ketamine and 4-6mg/kg xylazine, the 
animals underwent subcutaneous implantation of one sterile matrix in each flank (both of the 
same material). Afterwards, the wound was closed with sterile Michel suture surgical clips 
(7.5 mm x 1.75 mm, Fine Science Tools, Heidelberg, Germany). Then the animals were 
returned to the housing facility where they were kept under a 12h/12h light/dark cycle at 20°C 
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and 50% relative humidity and had free access to food (ssniff R/M-H, Lage, Germany) and 
water. 
In the first study, mice were sacrificed 2, 4, 8, 30 and 60 days post-operation (Table 4) by 
cervical dislocation and the matrices were excised. One cylinder served to evaluate tissue 
reactions by histological examination, while the other was used to investigate the swelling and 
microstructure of the matrix. In the second study, the equal procedure for sample collection 
was performed. The study designs with a detailed time schedule are shown in Tables 4 and 5. 
Early time points served for the evaluation of acute reactions, whereas later excision points 
were chosen for the investigation of chronic tissue reactions. 
Table 4: Time schedule for biocompatibility study of glyceroltripalmitate. 
group material n excision 
test group 1 100% Glyceroltripalmitate 4 d2, d4, d8, d30, d60 
test group 2 99% Glyceroltripalmitate 1% Gelatin 4 d2, d4, d8, d30, d60 
control group 1 100% Gelatin 4 d2, d4, d8, d30, d60 
control group 2 100% PLGA17 4 d2, d4, d8, d30, d60 
Table 5: Study design of erosion behavior investigations. 
group material n excision 
control group 1 100% Glyceroltripalmitate 4 d10, d20, d35 
test group 1 90% Glyceroltripalmitate 10% DSPC 4 d7, d14, d21, d25, d35 
test group 2 50% Glyceroltripalmitate 50% DSPC 4 d2, d6, d10, d15, d28 
control group 2 100% Cholesterol 4 d3, d7, d14, d24, d35 
test group 3 50% Glyceroltripalmitate 50% Cholesterol 4 d3, d7, d14, d24, d35 
test group 4 10% Glyceroltripalmitate 90% Cholesterol 4 d3, d7, d14, d24, d35 
 
One tissue sample from each mouse was fixed in Bouin´s solution, and processed for 
routine paraffin histology. Afterwards 6µm sections were stained according to the method 
detailed by Masson & Goldner and examined with an Olympus BH-2 light microscope 
(Olympus, Hamburg, Germany). The other matrix was detached from the surrounding tissue 
and then weighed on the above-described Mettler Toledo analytical scale to investigate its 
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swelling before being examined by light microscopy as described in section 2.16. After a 
freeze-drying step (see section 2.15), the matrices were weighed again to quantify erosion and 
subsequently re-examined by light microscopy. Swelling and erosion of the matrices were 
determined as relative change in mass compared to values before the implantation. Afterwards 
the freeze-dried matrices were manually broken into two parts and both the surface and cross-
section were imaged using scanning electron microscopy, as described in section 2.16. 
 
2.15 Freeze drying of matrices 
To determine the extent of erosion of the matrix material, the dry-weight after implantation 
was investigated. For the drying procedure of the matrices a Christ Beta 2-16 freeze drier 
(Martin Christ Gefriertrocknungsanlagen GmbH, Osterode am Harz, Germany) was used. The 
matrices were frozen to –40 °C over 3 hours before starting the main drying step, which was 
carried out for 24 hours at 8 °C and 0.05 mbar. For the final drying step, the samples were 
treated at room temperature and 0.005 mbar for two hours.  
 
2.16 Scanning electron microscopy (SEM) and light microscopy investigations 
Another important part of the in vivo investigations was the optical examination of the 
matrices after explantation. The samples were investigated by light microscopy with a M75 
zoom-stereomicroscope (Wild, Heerbrugg, Switzerland) and the microstructure of the 
matrices was examined by scanning electron microscopy (SEM). Samples were glued to 
aluminium sample holders (machine shop, University of Regensburg, Germany) using a 
conductive adhesive film (Leit Tabs, Ted Pella Inc., Redding, CA, USA) and gold sputtered 
for 4 minutes under argon atmosphere using a Polaron Automatic Sputter Coater E 5200 from 
Polaron Equipment Ltd. (Watford, UK). The coated samples were finally analyzed using a 
DSM 950 Scanning Microscope from Carl Zeiss (Jena, Germany). 
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2.17 Incorporaion of erosion modifiers and in vitro release set-up 
 To be able to modify the in vivo erosion of triglyceride matrices, several excipients were 
first tested in vitro for their influence on the release of pyranine from cylindrical 
glyceroltripalmitate matrices. Agarose was used in ratios of 5%, 10% and 15%, respectively, 
the phospholipids DMPC, DPPC and DSPC were chosen in concentrations from 5% to 50% 
(see Table 6) and sucrose was used in ratios of 5%, 10%, 25% and 50%. Before incorporation, 
the sucrose was sieved to four fractions of 25µm-45µm, 150µm-180µm, 250µm-355µm and 
560µm-710µm using analytical sieves (Retsch, Haan, Germany). 
For these experiments, two preparation methods were developed. The first was an 
emulsion method that has been previously described [37] and was only performed for the 
three phospholipids. Using this method, pyranine was dissolved in 200µl water and dispersed 
in a solution of the lipid and the respective amount of the phospholipid in 5 ml methylene 
chloride under vigorous vortex mixing (speed 8 vortex genie 2, Scientific Industries, 
Bohemia, USA). The resulting mixture was then sonicated for 30 seconds at a frequency of 20 
kHz and an intensity of 120 Watts using a B12 sonicator made by Branson (Sonic Power 
Company, Danbury, Connecticut, USA). Afterwards, water and solvent were removed from 
the resulting W/O emulsion by vacuum drying using the aforementioned two-stage oil pump 
until a final pressure of 0.5 Pa was reached. After drying, the mixture was ground in a mortar 
to obtain a free flowing powder with a particle size of less than 106µm.  
In the second preparation procedure, 135.0mg glyceroltripalmitate were loaded with 
15.0mg pyranine as described in section 2.6 and afterwards the predefined amount of the 
respective excipient was added in a second step. The resulting powder mixture was 
subsequently manually shaken in a 2.0ml micro test tube (Eppendorf, Hamburg, Germany) for 
one hour. Mixing in a mortar was not applied with regard to the defined particle size of the 
sucrose and consequently for the other materials to maintain the comparability of the results. 
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The obtained powders from both procedures were subsequently compressed to matrices as 
described in sections 2.4 and 2.6, respectively, and processed for in vitro release as mentioned 
in section 2.8.1. Table 6 gives an overview of the investigated ratios and applied preparation 
procedures for glyceroltripalmitate cylinders containing the three phospholipids as a 
modifying component. 
Table 6: Investigated ratios and preparation procedures for phospholipid containing glyceroltripalmitate 
matrices. The emulsion method was not performed for DMPC at ratios of 25% and 50%. The two 
step method was not used for DSPC and DMPC in the ratio of 50%. 
preparation method DMPC DPPC DSPC 
emulsion method 5%, 10% 5%, 10%, 25%, 50% 5%, 10%, 25%, 50% 
two step method 5%, 10%, 25% 5%, 10%, 25%, 50% -/- 
 
2.18 Particle size determination of lipid microparticles and powders before in 
vivo study 
After the in vitro experiments on various erosion modifiers, the hypothesis of a dependence 
of the in vivo erosion on the triglyceride particle size was investigated by using 
glyceroltripalmitate microparticles and powders. To perform particle size analysis of the 
triglyceride, the samples were investigated using a Mastersizer 2000 laser diffractometer 
(Malvern Instruments, Worcestershire, UK) as follows: approximately 100µg of the lipid 
sample were directly added to the dispersion unit (Hydro 2000S), which was filled with an 
ethanol / water mixture (68.2% (v/v), density 0.9). The particles were dispersed by stirring at 
3000rpm for 5min, no sonication was applied. The volume-based particle size distribution 
was calculated using the Fraunhofer approximation (Malvern Software V5.1). 
 
2.19 X-Ray diffraction analysis 
To investigate the degree of crystallinity of the glyceroltripalmitate microparticles and 
powders, which might also influence the in vivo erosion of the material, wide-angle X-ray 
scattering (WAXS) was performed for all samples by using a STOE STADIP X-ray 
diffractometer (Darmstadt, Germany) equipped with a copper anode (Cu Kα1 radiation, 
Germanium monochromator). Experiments were conducted at a scan rate of 2 theta = 0.05° in 
a 5° to 56° range and obtained data were analyzed using a Winxpow 1.08 software. 
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2.20 In vivo erosion study 
The third in vivo study investigated a dependence of the in vivo erosion on the triglyceride 
particle size using glyceroltripalmitate microparticles and two glyceroltripalmitate powders, 
one with a high and one with a low degree of crystallinity. Preparation of the microparticles 
by spray congealing was conducted as previously described [153]. The resulting lipid 
microparticles were sterilized by Beta-Gamma-Service (BGS, Saal a.d. Donau, Germany) 
using β-irradiation of 10MeV. The applied dose of radiation was 25kGy. 
To obtain the triglyceride powders for the in vivo experiments, two different sterilization 
processes were applied. In the first method, which led to a high degree of crystallinity, 
glyceroltripalmitate was heated for 2h to 160°C and afterwards tempered for 3 days at 55°C in 
the drying oven to obtain the stable β-modification [8]. Subsequently, the triglyceride was 
ground in a mortar and sieved to a particle size of 106µm to 250µm. These steps were 
performed under laminar airflow using a sterilized mortar and sieve, respectively. For the 
second sterilization method, the triglyceride was dissolved in chloroform and afterwards 
filtered through a PTFE sterile filter (Corning, New York, USA). Subsequently, the obtained 
solution was freeze dried in a sterilized desiccator, as mentioned in section 2.12, and the 
resulting powder was sieved as described above for the first sterilization method. 
From the sieved lipid microparticles and powders, 7.5mg portions were prepared in sterile 
micro test tubes (Eppendorf, Hamburg, Germany) for each mouse, to be implanted 
subcutaneously into the left flank with a sterilized pipette tip (Corning, New York, USA). 
Prior to this procedure, the mice were anaesthetized as described in section 2.14. The three 
groups were investigated in vivo for 8 weeks, using female immunocompetent NMRI-mice, 
which underwent subcutaneous implantation of the triglyceride into the left flank. Housing 
conditions were equal to former in vivo studies (see section 2.14). Samples were collected at 
days 7, 17, 28, 42 and 56. At these time points, the mice were sacrificed by cervical 
dislocation. Subsequently, the region of implantation was excised from the mice, samples 
containing the lipid microparticles or powders were fixed in 5% formaldehyde solution, and 
processed for routine paraffin histology as described in section 2.14. 
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2.21 Size determination for glyceroltripalmitate microparticles after in vivo 
study on erosion behavior of lipid microparticles and powders 
To investigate the erosion of the glyceroltripalmitate samples, the particle size and its 
alteration was observed throughout the course of the study. Particle size determination was 
carried out from histological sections using the described camera and software package with 
measurement module. Holes stemming from the microparticles and the triglyceride powder 
were measured by light microscopy using a Leica  DFC 320 camera and the IM1000 software 
package with measurement module (Leica, Heidelberg, Germany). To estimate the real 
diameter of the spherical particles in the respective histological section, two diameters 
(d1=smallest diameter, d2=largest diameter) were measured as shown in Figure 3, from which 
the mean was calculated. 
100µm
d1
d2
   
Figure 3: Light microscopy image of a histological section of lipid microparticles 7 days after implantation 
(HE stained, 100x). Mean diameter was calculated as (d1+d2)/2. 
But as Figure 4 illustrates, a significant statistical error would result if only the mean value 
of all measured diameters of the microparticles is calculated, since the observed diameter 
depends on the distance of the section from the central plane. Thus, in the depicted example 
cutting one particle in three different plane sections would result in three different diameters. 
Consequently, simply taking the mean value of all determined particle sizes within the in vivo 
study would result in diameters that differ from the real value. This is known and described in 
literature [156-158] as the so-called “Wicksell-corpuscle-problem”. 
 
Figure 4: Scheme of the so called “Wicksell-corpuscle- problem”, which occurs, when making plane sections 
of a sphere. 
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Stoyan, Kendall and Mecke described in literature [158] an estimator for the real diameter 
(shown in equation 1), which can be used for the analysis of the particle size of the lipid 
microparticle group. 
  (1) 
 vdˆ  estimated mean diameter of all measured particles 
 n number of particles which were measured 
 xi measured diameter of the respective particle. 
But since this estimator is valid only for spherical particles and the two lipid powders were 
irregularly shaped, it was only possible to obtain qualitative results for the lipid microspheres 
in our in vivo experiment. 
 
2.22 Manufacture of programmable implants and in vitro release study  
Since triglycerides were determined to be suitable for controlled prolonged release and the 
programmable implants developed by Vogelhuber et al. [39] were only capable of pulsatile 
release due to the used polyanhydride core matrix, investigations on programmable implants 
were carried out with glyceroltrilaurate, glyceroltrimyristate, glyceroltripalmitate, 
glyceroltristearate and cholesterol as core materials. The polymers described in section 1.1 
(PLGA10, PLGA17 and PLA30) were used as mantle materials. Table 7 gives an overview of 
the core and mantle materials used for the manufacture of programmable implants. 
Table 7: Used materials for the preparation of programmable implants. 
core materials mantle materials 
cholesterol PLGA10 
glyceroltrilaurate (C12) PLGA17 
glyceroltrimyristate (C14) PLA30 
glyceroltripalmitate (C16)  
glyceroltristearate (C18)  
 
1
1
1
2
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For the preparation of the matrices, first the respective core material was loaded with 
pyranine, as described in section 2.6. Afterwards, the cylindrical cores of 1mg weight and 
1mm diameter (Figure 5a) were compressed. The different matrix materials all contained 10% 
of the model drug. Schematics of the manual compression tools are shown in Figure 5.  
 
a)           b) c)
Upper punch
Punching tool
Bottom punch
 
Figure 5: a) manual press with 1mm diameter for manufacture of the core  
b) manual press with 2mm diameter and upper punch with plane shape  
c) upper punch with staggered shape. 
The powder was loaded into the appropriate manual compression tools and placed in the 
aforementioned hydraulic press; a compression force of 250N was applied and maintained for 
10 seconds. In the following step, the bottom of the mantle was prepared with 5.0mg of 
polymeric mantle material using the manual compression tool with a diameter of 2mm and the 
upper punch with the staggered shape (Figure 5b, c). Again a compression force of 250N was 
applied for 10 seconds. Afterwards the core was placed in the resulting cavity of the bottom 
part and the implant was compressed with another 1.5mg of the polymer as upper part for 10 
seconds with 250N using the plane upper punch (Figure 5b). The last step of the implant 
manufacture was the closure of the pores in the mantle, which could otherwise lead to a 
preliminary release [39], at a temperature above the glass transition point of the polymer. Two 
different methods to heat up the polymer mantle were tested and the results were compared. 
In the first method, the implants underwent a heat treatment in silicon oil (Rotitherm® H250) 
at 110°C for 3 seconds, whereas in the second method the press was heated in a drying oven 
and the implant was compressed subsequently with approximately 25N for 10 seconds. 
Applied temperatures were 48 °C for PLGA17 and PLGA10 and 50 °C for PLA30. Figure 6 
shows a schematic of the preparation procedure with the second compression step at higher 
temperatures. 
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Figure 6: Schematic of the preparation procedure for programmable implants; closure of pores within the 
mantle occurred through a second compression step at higher temperatures (here 48°C for PLGA10 
and PLGA17). 
Drug release was investigated from programmable implants as well as from the cores 
without mantle as described in section 2.6. Statistical calculations for the investigation of the 
onset of release was carried out by using one-way analysis of variance (ANOVA) in 
conjunction with Tukey´s studentized range test. 
 
2.23 Modelling of release profiles for preprogrammable implants 
In this study, the method of convolution, which has already been described [159-162], was 
utilized to predict release profiles from programmable implants and the results of the 
mathematical modeling were compared to experimentally obtained release profiles. 
Convolution and deconvolution are parts of the so-called system theory. Following the rules 
for this theory, the mantle of the programmable implants was handled as a “black box”, which 
reacts on an input function I(t) (e.g. the release of a model drug from a core matrix) with a 
specific response function R(t) (e.g. the release from embedded core). With the input function 
being a defined kinetic process (e.g. a bolus release from a core matrix), the system can be 
characterized by a system function, F(t) (filter function, impulse response). One impulse 
function is the so-called Dirac´s delta-impulse δ(t), which is a narrow rectangular impulse 
having the breadth T and the amplitude 1/T, which results in the value 1 for the area of the 
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delta-impulse. Mathematically, the relationship between the functions is described by the 
following equation:  
R(t) = F(t) ∗ I(t)  (2). 
The star indicates that the response function results from a convolution operation on filter- 
and input functions. The deconvolution can be expressed as follows: 
I(t) = R(t) // F(t)  (3) 
F(t) = R(t) // I(t)  (4). 
Consequently, an input function being the impulse δ(t), results in the following response 
function: 
δ(t) ∗ F(t) = F(t)  (5). 
With an amplitude having, for example, the value A, which differs from 1/T, the area of the 
impulse results in A·T. Such an impulse can generally be treated in the same manner as a 
Dirac-impulse, whose input- and response functions are described as A⋅Tδ(t) and A⋅T⋅F(t), 
respectively, which results in equation (6). 
A⋅Tδ(t) ∗ F(t) = A⋅T⋅F(t)  (6) 
An integratable function I(t) can be divided into pieces having the form A⋅Tδ(t), whereby 
the amplitude-value A is replaced by the value of the function I(iT) (Figure 7). 
0   T 2T 3T 4T 5T 8T 10T 15T 20T
t
I(t)
I(iT)
 
Figure 7: Dissection of the input function I(t) into rectangular impulses (adapted from [162]). 
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Considering the time-related shifting of the respective impulse, each of them becomes 
I(iT) · Tδ(t-iT), which results in equation (7). 
I(iT) · Tδ(t-iT) ∗ F(t) = I(iT) · T⋅F(t-iT)  (7) 
The response function R(t) now results from the overlapping of each single input function. 
Since F(t) is generally not as short as the delta-impulse and can be maintained for longer time 
periods, the previous intervals have to be taken into account. Considering an overlapping of 
all parameters results in: 
∑
=
−=
n
i
iTtFiTITnTR
0
)()()(   (8). 
With the intervals being very small, an integral can be formulated and the discrete time 
values iT can be replaced by the variable τ: 
∫ −=
t
dtFItR
0
)()()( τττ    (9). 
This integral is called convolution integral. A schematic of the relationship between input 
function, filter function and response function is depicted in Figure 8. 
system
input function
filter function
response function
I(t) R(t)
F(t)
a
  
F(t)
I(t)
R(t)
b
 
Figure 8: a) Schematic for a linear system, on which a convolution operation can be applied. For a known 
filter function, one special response function can be calculated for each known input function. 
(adapted from [162])  
b) Visualization of the transfer of convolution theory to programmable implants. 
Generally, for such systems it is valid that when two of the depicted functions are known, 
the third function can be calculated from the others. For the mathematical modeling in the 
investigations of programmable implants, the numerical solution of the convolution integral 
was applied. Thereby the input function or the filter function is considered to be constant 
within the respective time interval 0 ≤ T ≤ t. Starting with equation (8) for the numerical 
convolution, F(t) becomes the value F(nT) of the function. Thus it can be formulated that: 
I(iT) = Ii, F(nT-iT) = Fn-i, which leads from equation (8) to: 
∑
=
−
=
n
i
inin FITR
1
  (10). 
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Thus the numerical algorithm, which is depicted in equations (11-14), can be formulated as 
a solution of the convolution integral. This algorithm replaces the integration by 
multiplication and addition of numbers. 
TFIR ⋅⋅= )( 000       (11) 
TFIFIR ⋅⋅+⋅= )( 01101      (12) 
TFIFIFIR ⋅⋅+⋅+⋅= )( 0211202     (13) 
TFIFIFIFIR nnnnn ⋅⋅+⋅++⋅+⋅= −− )...( 011110   (14) 
Applying this algorithm, constant values for the input function and the filter function 
within the respective time intervals were considered. Thus, the values change at the transition 
to the next time interval (staircase algorithm). When I(t) should be calculated from the 
integral, a numerical solution is yielded from the inversion of the convolution, the so-called 
deconvolution. An algorithm can be formulated from equations (11-14). Thereby first I0 was 
calculated from equation (11), then the value was inserted into equation (12) and I1 was 
calculated. Knowing I1, I2 was obtained from equation (13) etc, leading to equations (15-18). 
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Values for the filter function were then calculated as follows: 
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Transferred to the programmable implants, convolution means the mathematical modeling 
of expected theoretical release profiles (=response function), when a core with known release 
properties (=input function) is embedded into a polymeric mantle (=filter function). Hence the 
effect of the respective polymeric mantle material was calculated by the use of data gained 
from core matrices made of cholesterol and embedded cholesterol cores, which showed 
pulsatile release. For PLA30, the calculation of the filter function was carried out using release 
data elaborated with a fast releasing polyanhydride by Vogelhuber in [39]. Time intervals of 
T = 1 day were chosen for the calculations. 
Since this mathematical method can only be applied for linear systems, the beginning of 
the mathematical modeling was fitted to the onset day of release. During the delay time, 
erosion of the polymeric mantle occurred and thus the filter would not have been linear. 
Changes within the mantle, taking place after the onset of release, were considered to be 
negligible in comparison to that occurring during the delay period. Due to this fact, the first 
value for the input function (I0 in equations 11-14) had to be the summarized release of the 
model drug until the day of the onset of release. Time-invariance, which is a second 
prerequisite, was taken for granted. 
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Introduction 
Lipid materials are widely investigated for their potential as an alternative to polymeric 
carrier materials for proteins and peptides. Their properties for controlled release are 
investigated by several groups [37,150] which obtained their data by simply measuring the 
concentration of the released model drug directly from the release medium, which was 
possible since non proteinic model drugs were used. But since there are several degradation 
pathways, that can affect proteins and peptides in solution during release, their stability in 
release buffer is of great importance to decide whether a long term release could be 
investigated directly from the release medium or if the incorporated drugs have to be 
extracted from the matrices, to determine the residue content for a subsequent calculation of 
the release data. Thus in these investigations firstly a stability study for insulin and 
somatostatin, which served as model drugs, was carried out. 
But in addition to occurring degradation processes in the release medium, the stability of 
proteins and peptides inside triglyceride matrices is of great interest. Since instability of this 
group of drugs was shown when incorporated into polymers [141], the triglycerides might be 
a promising alternative material. Insulin and somatostatin were incorporated as model drugs 
into lipid microparticles and release was investigated [118,153]. Thus an extraction of these 
two model drugs from the triglyceride matrix without the occurrence of degrading processes 
should become possible to enable the investigation of their stability within the triglyceride. 
Therefore, the extraction method developed by Lucke et al. [141] was tested and optimized 
using somatostatin and insulin as model drugs. Additionally a new procedure, to extract 
insulin and somatostatin from the glyceroltripalmitate matrices was developed. This new 
extraction method should protect the proteins and peptides from degradation, which can be 
caused by liquid phase separation during the procedure described in [141]. 
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Results and discussion 
Stability test and LC/MS-Analysis 
To investigate the stability of Insulin and somatostatin, the model drugs were incubated in 
phosphate buffer solution of pH 7.4 at 37°C, as described in section 2.2 Insulin showed good 
stability over two weeks, but after 5 weeks the fraction of unaffected protein decreased to 
approx. 66% (Figure 9). As Figure 10 shows, somatostatin was degraded continuously and 
even faster. Thus, at the final time point of the experiment less than 45% of the peptide had 
maintained its structure. 
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Figure 9: Degradation kinetics of insulin in phosphate buffer solution at 37°C over 35 days, data is shown as 
mean ± standard deviation, n=3. 
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Figure 10: Degradation kinetics of somatostatin in phosphate buffer solution at 37°C over 35 days, data is 
shown as mean ± standard deviation, n=3. 
In the case of somatostatin, the degradation product was identified via LC/MS-analysis as a 
deamidation product (Figure 11). The exchange of an amido-group (NH2) into a hydroxyl-
group (OH) led to an increase in the molecular mass of the somatostatin of 1Da, which was 
detected via the LC/MS-analysis. 
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Figure 11: HPLC-chromatogram of somatostatin with retention times and detected mass data from LC/MS 
(mass of somatostatin: 1637.7, mass of the deamidation product: 1638.7), small peaks at earlier 
retention times due to somatostatin and its deamitation product containing iso-aspartate. 
LC/MS-analysis of insulin showed no differences in the mass of insulin and the 
degradation product (data not shown). By carrying out GFC-analysis a second peak with 
earlier retention time, and thus a higher molecular mass was observed (see Figure 12). ESI-
MS, which was used for this analysis has a cut-off of 2000Da and detects masses above this 
cut-off as mass per charge (m/z). Thus, a molecule that is exactly twice as large as the insulin 
would be hidden in the same peak as insulin in ESI-MS. This lead to the conclusion that the 
observed degradation product was the non-covalent dimer of insulin. 
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Figure 12: GFC-chromatogram of insulin samples drawn at days 0 ( ), 3 (- -), and 35 (▪▪), respectively. 
These results made visible, that the determination of protein and peptide release from 
triglyceride matrices cannot be performed directly from the release medium, due to stability 
problems. Thus, an extraction method for the two model drugs from the triglyceride, in which 
they should be incorporated, was necessary for the investigation of a long-term release. 
Otherwise the number of errors would increase and thus detection of sensible values for the in 
vitro release would be impossible. 
 
Development of the new extraction method 
For the evaluation of the extraction method, insulin and somatostatin were first 
incorporated into glyceroltripalmitate matrices and afterwards extracted as described in 
section 2.5. First results using the extraction method described by Lucke et al. [141] revealed 
impossibly high extraction yields of above 100%, due to the higher amount of acetonitrile in 
the mixture and a subsequent dissolution of the solvent in the chloroform-phase. This led to a 
smaller volume of the water-phase and thus higher concentrations of the model drugs were 
detected. Therefore, in the case of insulin 0.01N HCl, which is a known good solvent for this 
protein was tested instead of the original solvent mixture. Additionally, a method without 
liquid phase separation was developed for both model drugs, since it has been stated in the 
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literature [140] that proteins and peptides may be degraded or denatured at liquid/liquid (l/l) 
interfaces. 
For insulin both methods produced good extraction yields with acceptable reproducibility. 
Somatostatin was also extracted to a good extent with very small deviations. For both the 
protein and the peptide the optimized solid/liquid extraction method using THF as solvent 
showed best results, compared to the other investigated solvents. Extraction yields of 94.5% 
for somatostatin with a standard deviation of 0.80% could be achieved. For insulin, extraction 
yields of 91.31% +/-5.11% and 96.33% +/-3.03% were achieved with the solid/liquid and the 
liquid/liquid extraction methods, respectively. 
Not only were good extraction yields observed, but also the stability of the model drugs 
during the extraction process was investigated within these experiments. Figures 13 and 14 
show HPLC-results for insulin (Figure 13) and somatostatin (Figure 14) standards in 
comparison with the two model drugs after the extraction from a triglyceride matrix. In both 
cases, no additional peaks were observed and no degradation products could be detected. This 
shows the suitability of the newly developed method for the investigation of the stability of 
these model drugs within a triglyceride matrix, such as lipid microparticles. 
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Figure 13: HPLC-chromatograms of an insulin standard solution ( , 50µm/ml) and insulin after the extraction 
from a glyceroltripalmitate matrix (- -). 
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Figure 14: HPLC-chromatograms of a somatostatin standard solution ( , 50µm/ml) and somatostatin after the 
extraction from a glyceroltripalmitate matrix (- -). 
 
Summary 
This study served to investigate how release profiles of the two model drugs insulin and 
somatostatin from triglyceride matrices can be determined. Due to the instability of insulin 
and somatostatin over 35 days within the release medium, no direct measurement of the 
released amount of the model drugs is possible. Thus, the necessity of their extraction from 
triglyceride matrices for the performance of controlled release studies was proven. A new 
method for the extraction of proteins and peptides from triglyceride matrices with good 
extraction yields was developed. This extraction method can be used for the determination the 
residue content with subsequent calculation of release profiles. Additionally the investigation 
of protein and peptide stability within the triglyceride matrices was facilitated, due to the 
avoidance of liquid phase separations during the extraction. This new extraction method could 
be of great use for the investigation of degradation processes of the drugs within the matrix, 
since the used peptide and protein were shown to be not affected during the extraction 
procedure. 
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Since the investigations carried out with proteins revealed stability problems and the need 
of drug extraction when release experiments are performed, fluorescent dyes, which were 
used successfully by Vogelhuber et al. [37], were chosen for future experiments. They can 
easily be incorporated into the triglyceride matrices. Concomitantly their quantification by 
fluorescence spectroscopy is very simple and sensitive and can additionally be performed 
directly from the release medium. Since the further release investigations served to investigate 
release mechanisms and influence factors, no proteins or peptides were needed as model 
drugs and thus we were able to facilitate investigations by the choice of the fluorescent dyes 
as new model drugs. 
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Introduction 
Information about expected release profiles will aid in the design of an implant for 
controlled release parenteral drug delivery. Thus, the manufacturing procedure, characteristics 
of the incorporated drug, and the release mechanisms from the matrix material were identified 
as central influencing factors in the liberation of drugs from triglyceride matrices. Therefore, 
investigations were carried out to identify crucial parameters during the manufacturing 
procedure, such as the compression force, the drug loading, and the drug distribution within 
the matrix or the implant surface. In the next step, their effects on the resulting release profiles 
were quantified. Concomitantly, the first results on the release mechanisms from 
glyceroltripalmitate were elaborated, whereby a special focus was placed on diffusion and 
osmosis. Additionally, the influence of the hydrophobicity of the model drug on its release 
from triglyceride cylinders was investigated by the use of fluorescein, which shows a pH-
dependent hydrophilicity and the lipophilic fluorescent dye nile red. Thereby it was 
investigated, whether release occurs slower with increasing lipophilic characteristics of the 
model drugs. Finally the uptake of water into the matrices was investigated qualitatively and 
quantitatively over a period of 14 days. 
 
Results and discussion 
Crucial factors for the design of triglyceride matrices for controlled release 
1. Compression force 
For the investigation of the preparation procedure with respect to the influence of several 
parameters on the resulting release profiles, matrices containing pyranine, a highly water 
soluble fluorescent dye as model drug, were manufactured under various conditions. The 
investigated parameters were drug loading, compression force, surface area and drug 
distribution within the matrices. Lipid cylinders, which contained 10% pyranine and which 
were compressed with 250N, released the dye within 17 weeks (Figure 15). While an 
increased compression force of 500N led to similar results, the lower force of 50N accelerated 
the release significantly. In that case, the complete liberation of the dye after one week 
(Figure 15) was observed. This indicated the existence of a threshold for the applied force in 
the compression step during the manufacturing procedure. Below this threshold, a change of 
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the compression force leads to significant changes in the release properties of the 
manufactured matrix, but above 250N the compression force seemed to effect the resulting 
release profile from the glyceroltripalmitate cylinder only negligibly. 
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Figure 15: Release profiles from 10% pyranine containing glyceroltripalmitate matrices prepared with 
compression forces of 50N (- -), 250N ( ) and 500N (▪▪), respectively. The diameter and height of 
the matrices were 2mm and 4mm, respectively; dye incorporation occurred via co-lyophilization 
method, values represent mean ± standard deviation (n=5). 
 
2. Drug-loading 
Different dye loadings were shown to have a tremendous effect on the release properties of 
the triglyceride matrices (Figure 16). For this comparison, all of the cylinders were 
compressed with a force of 250N. As mentioned above, the matrices containing 10% pyranine 
released the dye over 17 weeks; however, an increase of drug loading up to 33% led to a 
complete release within the first day. When the dye content within the matrices was decreased 
to 1%, release was not completed and less than 13% of the incorporated pyranine was 
liberated over the investigated period of 19 weeks. Release of the 1% loaded cylinders was 
not finished after this time period, but continued slowly. These results confirmed the fact that 
drug loading is an important factor for lipid matrix manufacture, too. 
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Figure 16: Release profiles from glyceroltripalmitate matrices with a diameter of 2mm and 4mm in height 
containing 1% (▪▪), 10% ( ) and 33% (- -) pyranine, prepared by co-lyophilization. A compression 
force of 250N was applied; data is expressed as mean ± SD (n=5). 
It was observed that long-term release can be achieved with drug loadings of up to 10%. 
Referring to percolation theory [163,164], it is likely that there is a threshold for the drug 
loading as well, above which very fast and pulsatile release from the triglyceride matrices 
occurs. The theory generally deals with clusters of randomly occupied sites in a lattice [165]. 
It describes crystal structures as well as, for example, the formation of a network when a 
substance is incorporated into a matrix. Transferred to controlled release devices, the 
percolation theory can be used to describe the influence of drug-loading on its release from a 
matrix system. Requirements for, and characteristics of the formation of a network within 
such matrices [166,167] are discussed as well. 
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3. Drug distribution within the matrices 
Another important parameter for the release of a drug from the glyceroltripalmitate 
matrices could be the distribution of the drug within the cylinder. When mixing a powder with 
a small amount of another powder, the homogeneity of the mixture decreases with the 
increasing particle size of one of the compounds [164]. Thus, this parameter was varied via 
the particle size of the triglyceride. A decrease in the lipid particle size was considered to lead 
to a better distribution of the drug within the matrix and vice versa. In these experiments the 
effect of the dye distribution within the matrices on the release properties was investigated. 
Again a dye load of 10% was used and 250N were applied for the compression step during the 
preparation procedure. Dispersity of the model drug increases with decreasing size of the 
triglyceride. Thus, the distribution of the pyranine was considered to be best for the matrices 
prepared using the co-lyophilization method (see section 2.6), which was usually performed 
for the incorporation of the model drug, compared to that within matrices prepared by mixing 
lipid and dye powders and compressing the mixtures to cylinders. This was confirmed by the 
in vitro release results. Consequently, release accelerated significantly when lipid particle 
sizes increased (Figure 17). Using triglyceride particle sizes from 106µm to 250µm, the whole 
dye content was released after just one week (Figure 17). Reduction in the size of 
glyceroltripalmitate particles for the preparation of the matrices below 106µm led to a much 
slower release. Drug liberation was finished after 4 weeks of incubation (Figure 17). 
Decreasing the particle sizes, which resulted in molecular dispersity of the dye within the 
matrices, the mentioned controlled release over 17 weeks was achieved. This again confirmed 
the tremendous influence of the drug distribution on the release properties of the 
glyceroltripalmitate matrices. These investigations revealed the incorporation by freeze-
drying both the lipid and the model drug in one solution as most successful for prolonged, 
controlled release. 
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Figure 17: Release profiles from 10% pyranine containing glyceroltripalmitate matrices prepared from 
triglyceride of differing particle sizes. A compression force of 250N was applied, the diameter and 
height of the matrices were 2mm and 4mm, respectively; values represent mean ± SD (n=5). 
 
4. Surface/volume ration of the matrices 
To investigate the influence of the surface/volume ratio of the matrix on the resulting 
release profiles, cylinders with varying diameter and height were produced. In the release 
profiles it was seen that the height of matrices had no significant effect on the release 
properties of the triglyceride cylinders (Figure 18). Release profiles showed similar shapes 
comparing cylinders with heights of 2mm, 4mm and 6mm and liberation of the dye from the 
matrices occurred over the same time period of approximately 17 weeks. 
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Figure 18: Release profiles from 10% pyranine containing glyceroltripalmitate matrices of 2mm diameter and 
varying cylinder height. Cylinders were prepared with co-lyophilization method, a compression 
force of 250N was applied; data is shown as mean ± standard deviation (n=5). 
Since these results revealed no significant effect of little variations in the surface areas of 
the matrices on the release profiles from the glyceroltripalmitate cylinders of 2mm diameter, 
smaller matrices with a diameter of 1mm and a height of 2mm were produced to achieve 
larger variations in the surface/volume ratio and to compare the release profiles. Table 8 
shows the variation of the cylinder surface in correlation with the diameter and the 
surface/volume ratio. 
Table 8: Geometry data of matrices with varying height and diameter. 
diameter height surface area surface/volume ratio 
2mm 2mm 18,85mm2 3 [1/mm] 
2mm 4mm 31,42mm2 2,5 [1/mm] 
2mm 6mm 43,98mm2 2,33 [1/mm] 
1mm 2mm 6,91mm2 7,33 [1/mm] 
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Investigation of matrices with higher value for the surface/volume ratio demonstrated, in 
contrast to first release results, an acceleration of the release with increasing surface/volume 
ratio (Figure 19). Release profiles resulting from matrices with 1mm diameter and 2mm 
height showed that the reduction in the diameter led to complete release after 8 weeks, in 
comparison to 17 weeks of release from cylinders with a diameter of 2mm and a height of 
4mm. 
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Figure 19: Release profiles from 10% pyranine containing glyceroltripalmitate matrices of 1mm diameter, 2mm 
height (- -) and 2mm diameter, 4mm height ( ).  
Matrices were prepared with co-lyophilization method, a compression force of 250N was applied; 
values are expressed as mean ± SD (n=5). 
These results revealed the diameter of the cylinders, but not the height of matrices as an 
important factor for the design of controlled release devices made of glyceroltripalmitate. 
Thus height of the matrices can be a very useful tool for the adjustment of the drug dose, 
which is desired to be applied, because its variation would not lead to an alteration of the 
resulting release profile. 
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5. Drug characteristics 
These results revealed that the diameter of the cylinders, but not the height of matrices, is 
an important factor for the design of controlled release devices made of glyceroltripalmitate. 
Thus height of the matrices can be a very useful tool for the adjustment of the drug dose to be 
applied, because its variation would not lead to an alteration of the resulting release profile. 
In addition to the investigated parameters concerning the manufacturing procedure and the 
characteristics of the matrix itself, the incorporated drug also affects its release from lipid 
matrices. Thus in the following experiments the hydrophilicity of incorporated model drugs 
was investigated for its influence on the resulting release profiles. 
Fluorescein-di-sodium salt, a highly water-soluble fluorescent dye, which has different 
hydrophilicity at different pH-values, was chosen as model drug. Due to its two acidic groups 
(Figure 20) with pka-values of 4.65 and 6.98, at pH 2.8 fluorescein is neutral, whereas at pH 
5.5 one and at pH 9.0 both acidic groups are deprotonated and thus the mono- and di-anion 
forms occur, respectively. Concomitantly, the release of nile red, a highly lipophilic 
fluorescent dye, was investigated. A solubility of nile red in phosphate buffer (pH 7.4) of 
0.7ng/ml was determined as described in section 2.7. 
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H H
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Figure 20: Structures and charges of fluorescein and its ionic forms at different pH-values. 
Figure 21 shows distinct correlations between the degree of ionization of fluorescein and 
release profiles. The liberation of the di-anion occurred most quickly, followed by the release 
of the mono-anion, whereby the difference between release results for the two ionic forms of 
fluorescein was only slight. However, liberation of the protonated and thus neutral fluorescein 
molecule from glyceroltripalmitate matrices at a pH value of 2.8 occurred much slower. In 
Figure 21 it can also be seen that release of the two ionic forms of fluorescein is completed 
after 23 days, whereas cylinders incubated at pH 2.8 released only approximately 21% of the 
dye within 80 days. Liberation from these implants was still ongoing at a low level. 
Concerning the release of nile red, the lipophilic model dye, no release was observed during 
the investigated period of 4 weeks (Figure 21). 
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Figure 21: Release profiles from glyceroltripalmitate matrices with a diameter of 2mm containing 10% 
fluorescein-di-sodium salt and 10% nile red. Fluorescein matrices were incubated in phosphate 
buffers of different pH values; data represent mean ± SD (n=5). 
 
Release Mechanisms 
1. Osmotic effects 
While several crucial parameters for the design of lipid implants as controlled release 
devices have been identified and characterized, the release mechanisms from triglyceride 
matrices are not yet clear. Thus further investigations were carried out to gather information 
on processes that occur during the release of drugs from triglyceride matrices [168]. 
Therefore, in one experiment, glyceroltripalmitate cylinders with a diameter of 2mm 
containing 10% fluorescein-di-sodium salt were prepared and incubated in phosphate buffers 
of varying osmotic pressures. Release data obtained from these investigations should 
elucidate whether osmosis is involved in release processes of the model drug from the 
matrices. Release results are shown in Figure 22. Distinct effects on release profiles were 
observed when the osmotic pressure of the release medium was increased from 290mosmol to 
either 7850mosmol or 9500mosmol. 
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Figure 22: Release profiles from 2mm diameter glyceroltripalmitate matrices containing 10% fluorescein-di-
sodium salt, incubated in phosphate buffers of different osmotic pressures (adjusted by NaCl-
addition) at ph 9.0; data is shown as mean ± standard deviation (n=5). 
Comparing osmolarities of 7850mosmol and 9500mosmol, release profiles differed only 
during the first period, whereas after 5 days no major differences were observed. An increase 
in osmotic pressure of the release buffer led to slower release during the first 2 days, resulting 
in release rates of 53%, 36% and 27% for media with osmolarities of 290mosmol, 
7850mosmol and 9500mosmol, respectively. Additionally, the higher osmotic pressure 
resulted in a lower amount of totally released dye (Figure 22). This indicated the occurrence 
of “osmotic pumps” during release, which lost effectiveness with decreasing amounts of dye 
within the matrix.  
Figure 23 shows a schematic of the function of “osmotic pumps”, which can be involved in 
release mechanisms from triglyceride matrices. Osmotic effects can occur when the solvent 
reaches the model drug within the matrix though pores or by diffusion through the matrix 
material and dissolves it. At the interface of the drug particles, their dissolution results in a 
saturated solution and thus in a very high osmotic pressure. Along this osmotic gradient, the 
model drug can be pumped out of the matrix and thus osmosis can be one important factor for 
the release of any drug from triglyceride matrices. Even though sink conditions were 
generated during the release study, a decreased solubility of the model drug within the release 
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pathways of the matrix at higher osmotic pressures may also play a role in the resulting 
release profile. 
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Figure 23: Schematic of an osmotic pump occurring during release from triglyceride matrices. Particles within 
the cylinder represent the model drug, which is dissolved and released along an osmotic gradient 
into the release medium. Uptake of the medium into the matrix was not classified, but may occur by 
diffusion through the matrix material or through pores. 
 
2. Water uptake and pore formation 
In the second experiment for the investigation of release mechanisms from lipid matrices, 
cylinders without any drug loading were manufactured from glyceroltripalmitate of different 
particle sizes, according to the experiments described above. Matrices prepared of lyophilized 
triglyceride, lipid powder with particles below 106µm and 106µm-250µm of size, were 
incubated for 14 days in fluorescein-di-sodium salt containing phosphate buffer. Fluorescence 
within the matrices was examined at specific time points to obtain information on the water 
uptake into the matrices and to investigate the occurrence and extent of pore formation 
processes. The aspect investigated in these experiments into the release mechanisms from 
triglyceride matrices, was the water uptake into cylinders prepared from glyceroltripalmitate, 
which gives information on the occurrence of pore formation processes. In the first step, water 
uptake was quantified, not to obtain exact results on the amount of water within the matrices, 
but to investigate whether differences in pore formation can be observed when using 
triglyceride powders of varying particle sizes. 
In Figure 24 the relative amount of water taken up by the lipid cylinders, and thus the 
variance in the extension of pore network, is shown. Even though water uptake was low and 
thus standard deviations foiled significance, a tendency could be observed. These results 
elucidated a correlation between the porosity of the glyceroltripalmitate matrices and particle 
size of the triglyceride powder. 
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Figure 24: Comparison of water uptake into lipid matrices prepared of glyceroltripalmitate of varying particle 
size; values are expressed as mean ± SD (n=5). 
In the second step, blank triglyceride matrices were incubated in phosphate buffer 
containing fluorescein-di-sodium salt at pH 9.0 for 14 days. Afterwards the cylinders were 
freeze dried, cross-sectioned (see section 2.10) and investigated by confocal laser scanning 
microscopy. In this way, the existence of pores was visualized through the imbibed 
fluorescence of the dye. In Figure 25 confocal laser scanning microscopy pictures of matrices 
compressed from lyophilized glyceroltripalmitate and triglyceride powder with particle sizes 
below 106µm, respectively, are shown. Matrices prepared from the ground and sieved powder 
displayed fluorescence in outer regions after 4 hours, which spread regularly over the whole 
matrix during the first day (Figure 25a,b). Cylinders compressed from larger triglyceride 
powder particles showed similar results, whereas in case of matrices compressed from the 
lyophilized triglyceride, fluorescence was only detected at the edges of the cylinders and no 
diffusion into central regions was observed during the investigated period of 14 days (Figure 
25c). 
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Figure 25: Confocal laser scanning microscopy image of cross sections of glyceroltripalmitate matrices after 
incubation in buffer containing fluorescein-di-sodium salt, a) lipid powder <160µm, after 4 hours; 
b) lipid powder <160µm, after 1day; c) lyophilized glyceroltripalmitate, after 14 days. 
These results indicated that a more distinct pore network formed when triglyceride 
matrices are compressed from powders with bigger particle sizes, which agrees with the 
above-described results of the water uptake and with release data obtained from pyranine 
loaded lipid matrices. 
 
Summary  
In these investigations, the crucial parameters for the lipid matrix manufacture were 
identified and their influence on the resulting release profiles was quantified with the intent to 
evaluate the preparation procedure for cylindrical glyceroltripalmitate matrices for controlled 
release drug delivery. Drug loading, as well as compression force, drug distribution and the 
surface/volume ratio of the release system, were identified as crucial parameters for the 
design of triglyceride matrices as controlled release devices and for their preparation 
procedure. Concerning drug loading, the existence of a threshold higher than 10% was shown, 
below which controlled release over several months was achieved. For the compression force, 
a threshold was observed, too. Above 250N the influence of the compression force on the 
resulting release profile was negligible. Concomitantly, these investigations revealed that 
better drug distribution leads to longer release periods and thus should be maximized for 
prolonged release. The surface/volume ratio was revealed as an important and useful tool to 
vary the release profile of the developed matrix. It can easily be adjusted over the diameter of 
the cylindrical matrices and consequently the release period of an incorporated drug can be 
prolonged by increasing the matrix diameter. However the height of the cylinder was 
demonstrated to be a less important factor. This facilitates the variation of the applied dose, 
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which can thus be adjusted by changing the weight of the matrix, whereby the expected and 
desired release profile can be maintained. 
The investigations also pointed out the severe influence of the characteristics of the 
incorporated drug on the release profile. An indirect dependence of the release period on the 
drug hydrophilicity was observed, leading to slower release of more lipophilic substances 
from a triglyceride matrix. In addition to the time within which controlled release occurred, 
the degree of totally released model dye was also shown to be directly dependent on the drug 
hydrophilicity. Thus the highly lipophilic model drug nile red was retained within the 
triglyceride cylinder. 
Considering the release mechanisms from triglyceride matrices, the occurrence of osmotic 
processes during drug release and their involvement in the transport of the incorporated drug 
within the triglyceride cylinder was clearly elucidated. Release of the model drug from the 
matrices was slower at increased osmotic pressures of the release medium. Thus, when 
incorporating any drug into a triglyceride matrix, the osmotic pressure resulting from its 
saturated solution has to be taken into account, due to its influence on the resulting release 
profile. 
Concomitantly, it was shown that pore formation within triglyceride matrices directly 
depended on the lipid particle size used for the preparation of the cylinders. Pore formation 
was more distinct in matrices compressed from ground and sieved lipid powder compared to 
matrices prepared from lyophilized glyceroltripalmitate. The extension of pore formation 
within the triglyceride matrices is of great importance for controlled release, because pores 
allow for faster diffusion within the matrix and thus accelerate drug release. 
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Inroduction 
In the treatment of many diseases, such as brain tumors, acromegaly, or diabetes mellitus, 
the controlled release of a medication over weeks or months is desirable to facilitate therapy 
and increase patient compliance [169,170]. Consequently, a plethora of controlled release 
forms have been investigated, such as nano- and microparticles and implants. Currently, 
commercially available implantable delivery systems are frequently made of biodegradable 
polymers. They possess many positive characteristics, such as good biocompatibility [136-
138], a chemical structure that results in diverse release properties, biodegradability, and well-
defined degradation pathways. However, some of these materials expose drugs to a changing 
microenvironment inside the eroding implants with acidic pH [139], increased osmotic 
pressure [139], or degradation products that can affect the stability of incorporated 
compounds, especially proteins and peptides [141]. Therefore, alternative materials, such as 
hydrogel materials, have been investigated [171,172] and recently much attention has been 
given to lipophilic substances such as cholesterol, phospholipids, mono-, di- and triglycerides 
or mixtures of these materials [173,174]. Cholesterol and triglycerides have been successfully 
used for controlled drug release over several weeks [8,36]. However, their biocompatibility 
has not yet been investigated. Therefore, we decided to examine the tissue reactions of mice 
to subcutaneously implanted lipid matrices. Although microparticles have a small size, round 
shape and smooth surface, and thus reduce mechanical irritation, we decided to use cylindrical 
macroscopic implants for in vivo experiments to facilitate recovery of the implant. We chose 
glyceroltripalmitate for our investigation into triglyceride biocompatibility and compared it to 
PLGA and gelatin, which are considered to be well tolerated. Furthermore, the in vivo erosion 
behavior of the triglyceride and the effects of incorporated erosion-modifying components 
were investigated. Due to their promising release characteristics [36,175], cholesterol and 
distearoyl-phosphatidyl-choline (DSPC), a phospholipid with two stearic acid side chains, 
were chosen to serve as erosion modifiers in this study. 
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In vivo biocompatibility study 
We first investigated the in vivo behavior and tolerance of pure triglyceride implants. Time 
points for the explantation were days 2, 4 and 8 for the investigation of acute reactions and 
day 30 and 60 to detect chronic tissue reactions. Gelatin and PLGA were chosen as controls 
with known good biocompatibility. In a second test group, the triglyceride implants were 
supplemented with 1% gelatin, which can serve as a hydrogel-forming carrier for highly 
potent substances like growth factors [176]. The time schedule for this biocompatibility study 
is given in Table 4 (see section 2.14). Although implants made of pure gelatin were already 
eroded at day 2, the defined outlines of the implants were visible until day 4 and good 
biocompatibility was observed in all histological sections. One cell layer of connective tissue 
formed around the implant, but no increase in inflammatory cells was observed (data not 
shown). Recovery of the PLGA implants was possible up to day 30, whereas after 60 days the 
material was completely eroded and no implant residues could be found in the subcutaneous 
tissue. Histological investigations of the polymer implant also revealed good tolerance, 
evidenced by the minimal encapsulation by connective tissue (1 to 5 cell layers) and no 
adverse reaction, such as an increase in inflammatory cells (data not shown). Because the Tg 
of PLGA17 (Tg = 46 °C) is near the body temperature of the mice (36,5-38°C, [177]), the 
implants underwent deformation and lost their cylindrical shape (Figure 26), which led to less 
mechanical irritation and thus to a reduction of foreign body reaction [178]. 
2 mm
 
Figure 26: Light microscopy image of a PLGA implant excised at d2. 
The implants of the two test groups remained stable over 60 days and maintained their 
cylindrical shape. Implants prepared with and without gelatin showed similar results 
concerning the tissue reactions; therefore, only histological pictures of pure 
glyceroltripalmitate implants are shown (Figure 27). Encapsulation in connective tissue by 
abundant fibroblasts was observed in both groups and became more apparent with time. A 
histological section of the typical tissue response to a glyceroltripalmitate implant 4 and 30 
days after implantation is shown in Figure 27. At days 30 and 60 the thickness of the capsule 
amounted to 5 to 10 cell layers compared to 1 to 5 layers at the earlier time points. The 
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intensity of the encapsulation into connective tissue was comparable to that of the PLGA 
implants. In a few histological sections at early excision points of the two test groups, isolated 
foreign body giant cells or macrophages were seen, but for the most part no increase of 
inflammatory cells was observed. This rarely occurring mild foreign body reaction, which 
was restricted to the interface and regions very close to the implant surface, may not 
necessarily be related to the material, but rather be induced by mechanical irritation of the 
subcutaneous tissue due to the rough edges of the cylindrical implants [178]. Apart from 
collagenous encapsulation 30 and 60 days after implantation, no further reaction of the 
organism to the implants (e. g. increase in mononuclear cells) was observed in either the 
subcutaneous tissue adjacent to the implants or in other sites in the animals. 
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Figure 27: Light microscopy images of a typical tissue response to glyceroltripalmitate implant at day 4 (left) 
and at day 30 (right), Masson & Goldner stained, both 400x, region of the implant marked at the left 
side. 
When the stability of the implants was examined, it was seen that the triglyceride matrices 
showed no significant swelling and only a slight increase in dry weight 2, 4, and 8 days after 
implantation (Figure 28). This may be due to the adhesion of connective tissue that could not 
be completely removed before drying and weighing of the implants. At days 30 and 60, when 
the implants were completely encapsulated by connective tissue, a more distinct rise in the dry 
weight of the matrices was observed (Figure 28), which demonstrates the stability of the 
implants over the entire time period and their suitability for a long-term release. 
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Figure 28: In vivo erosion and swelling of glyceroltripalmitate matrices, normalized to the pre-implantation 
weight, data is shown as mean ± standard deviation, n=4. 
SEM pictures showed that the surface of the pure triglyceride matrices became absolutely 
smooth (Figures 29,30), adhered particles were no longer seen and grooves, caused by the 
steel compression tool, disappeared over the 30-day implantation period. Few remnants of 
connective tissue that could not be removed were seen, due to the encapsulation of the 
implants in the subcutaneous tissue in mice. Cross-sections of implants made of pure 
glyceroltripalmitate (Figures 29,30) showed no alteration in the microstructure. Neither signs 
of degradation, such as pore formation, nor changes in the crystal structure were observed. 
Implants containing 1% gelatin, however, showed slight signs of erosion, due to the 
degradation of the water-soluble compound (Figures 31,32). This was apparent in the 
formation of pores and cavities, which also led to disruptions in the lipid implants. This again 
demonstrated the stability of the implants, but also showed that the erosion of the triglyceride 
implants can be influenced by incorporation of a water-soluble compound into the matrix. 
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Figure 29: Top view (left, 45x) and cross-section (right, 100x) of glyceroltripalmitate matrix before 
implantation. 
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Figure 30: Top view (left, 45x) and cross-section (right, 100x) of glyceroltripalmitate matrix excised at day 30. 
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Figure 31: Top view (left, 45x) and cross-section (right, 100x) of glyceroltripalmitate implant containing 1% 
gelatin before implantation. 
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Figure 32: Top view (left, 45x) and cross-section (right, 100x) of glyceroltripalmitate implant containing 1% 
gelatin excised at d30. 
 
In vivo erosion study 
Even though the observed in vivo stability of glyceroltripalmitate is a positive result, 
because the material is suitable for long-term release applications, the erosion of the material 
would eventually have to be accelerated to generate an applicable biodegradable device and to 
obtain a greater variability. With regard to the in vitro release characteristics [36,175], 
cholesterol and DSPC were chosen to investigate their influence on the erosion behavior of 
glyceroltripalmitate. To examine the in vivo effects of the phospholipid, two different ratios 
of glyceroltripalmitate and DSPC were investigated. Implants were manufactured that 
contained 10% and 50% (w/w) of the phospholipid. As a second non-polymeric material with 
slightly amphiphilic characteristics and known good properties for controlled release [36], 
cholesterol was mixed with glyceroltripalmitate in ratios of 1:1 and 9:1 and the resulting 
mixtures were investigated for their in vivo erosion behavior. The duration of the study was 
up to 35 days and again time points in the early stage were chosen in addition to that at the 
end of the study to obtain data for acute tissue response. A detailed time schedule of the study 
is depicted in Table 5 (see section 2.14). 
In this experiment, the addition of cholesterol did not lead to any change in the erosion of 
glyceroltripalmitate. All implants of the cholesterol groups remained stable, maintained their 
cylindrical shape, and displayed no evidence of significant erosion. SEM photographs showed 
similar behavior in these implants as was described above for the glyceroltripalmitate 
implants. There was no observable change in the microstructure or pore formation (Figure 
33). 
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Figure 33: Cross-section of 100% cholesterol matrix before implantation (left) and excised at day 35 (right), 
both 150x. 
Implants containing DSPC showed distinct swelling and erosion in both ratios, 
demonstrated through both an increase in wet weight and a loss in weight after freeze drying 
of the implants (Figures 34,35). The strong adherence of some connective tissue that could 
not be removed caused a very high standard deviation in the measured implant masses of the 
50% DSPC implants at day 28. 
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Figure 34: In vivo erosion ( ) and swelling (- -) of triglyceride matrices containing 10% DSPC, normalized to 
1.0 by pre-implantation mass; values are expressed as mean ± SD (n=4). 
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Figure 35: In vivo erosion ( ) and swelling (- -) of triglyceride matrices containing 50% DSPC, normalized to 
1.0 by pre-implantation mass; values are expressed as mean ± SD (n=4). 
The constructs with the higher phospholipid content had already lost their cylindrical shape 
6 days post-implantation and distinct signs of erosion like pore formation were observed by 
SEM throughout the course of the study. Figures 36-39 show the changes in these matrices 
over the course of the study. show the changes in these matrices over the course of the study. 
Two days after implantation, a few pores and slight changes in microstructure of the implants 
were already observed; the implant collapsed at day 6 and distinct cavities were still visible at 
day 28. 
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Figure 36: SEM images of the top view (left, 40x) and cross-section (right, 150x) of 1:1 
glyceroltripalmitate:DSPC matrix before implantation. 
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Figure 37: SEM images of the top view (left, 40x) and cross-section (right, 150x) of 1:1 
glyceroltripalmitate:DSPC implant excised at day 2. 
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Figure 38: SEM images of the top view (left, 25x) and cross-section (right, 150x) of 1:1 glyceroltripalmitate: 
DSPC implant excised at day 6. 
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Figure 39: SEM images of the top view (left, 25x) and cross-section (right, 150x) of 1:1 
glyceroltripalmitate:DSPC implant excised at day 28. 
These observations clearly demonstrated the influence of the DSPC on the accelerated 
erosion of the triglyceride implants. However, a foreign body reaction at the implantation site 
was observed when DSPC was incorporated into the matrices. This mild tissue response was 
Chapter 5  In vivo Biocompatibility and Erosion Behavior 
 -81-  
seen in the form of a slight increase in the presence inflammatory cells, such as foreign body 
giant cells, and was not evident in the implants containing only 10% DSPC. At the end of the 
study, only connective tissue producing fibroblasts were observed, which indicates that the 
inflammatory reaction was an acute tissue response (Figure 40). Comparable tissue reactions 
showing a slight foreign body reaction, noticeable through the appearance of a few 
inflammatory cells, primarily foreign body giant cells, have already been reported for 
biodegradable polymers [179-181], whose biocompatibility is accepted to be at least 
satisfactory. Implants containing 50% phospholipid resulted in a more persistent 
inflammatory reaction, in which both foreign body giant cells and granylocytes were visible 
and a chronic tissue response with an increase of inflammatory cells and mononuclear 
infiltrates (Figure 41) was observed. Thus, this inflammatory reaction appears to be dependent 
on the amount of the phospholipid present and the tissue response is not related to the 
triglyceride. It might be caused by the surfactant characteristics of the DSPC or due to the 
increased roughness of the implant surface followed by increased mechanical irritations, 
which might also lead to an increase in foreign body reactions [178]. 
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Figure 40: Light microscopy images of histological sections of implants containing 10% phospholipid at day 7 
(left, 200x) and day 35 (right, 400x), Masson & Goldner stained, region of the implant marked. 
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Figure 41: Light microscopy images of histological sections of 50% phospholipid containing implant at day 2 
(left, 200x) and day 28 (right, 400x), both Masson & Goldner stained, arrow marks a local 
connective tissue proliferation, double arrows mark granulocytes. 
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Summary 
Glyceroltripalmitate was shown to be biocompatible in vivo, since neither a significant 
inflammatory response nor a cytotoxic reaction was observed in mice over a period of 2 
months. Furthermore, cholesterol emerged as a well-tolerated material when implanted 
subcutaneously, although the attempt to influence the (very slow) erosion rate of the 
triglyceride by mixing it with cholesterol failed. Distinct signs of implant degradation were 
achieved by using 1:1 mixtures of DSPC with glyceroltripalmitate, but in these concentrations 
a foreign body reaction was observed. As further aspects influencing the degradation time of 
the triglyceride, the size of the implanted material, crystallinity, and surface structure are 
discussed in the following. Additionally, the influence of phospholipids with shorter fatty acid 
chains and other molecules, such as hydrogel-forming substances, which could function as 
erosion modifiers on the in vitro release, was investigated. 
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Introduction 
Since in vivo degradation of macroscopic lipid matrices occurred only slowly, 
investigations were carried out with the goal of accelerating the erosion of the triglyceride. As 
the experiments described in chapter 5 showed, one possibility to overcome the problem of 
slow matrix degradation might be the incorporation of excipients, such as the phospholipid 
DSPC, into the triglyceride matrices. Thereby different strategies can be followed depending 
on the chosen release modifier. 
(i) The use of amphiphilic molecules might accelerate the degradation of the lipid matrices 
by increasing the weakness of the matrix material (e.g. through a decrease in melting point) 
and facilitating the emulsification of the triglyceride. (ii) Hydrogel forming agents, which 
show swelling in contact with water, can serve as disintegrating excipients, which cause 
breaking of the matrices. Since in the literature indications can be found that lipid 
microparticles show faster erosion than matrices in the described investigations [118], (iii) 
incorporation of hydrophilic porogens could be another possibility to accelerate the erosion of 
the cylindrical triglyceride matrices. Such excipients decrease the stability of the matrix, when 
leached out, and thus can lead to the collapse of the cylinder into smaller particles upon 
exposure to mechanical stress, as occurs in vivo. Afterwards these fragments may undergo 
faster in vivo degradation than solid cylinders. 
Hydrogel forming agents and hydrophilic porogens both cause a fragmentation of the 
matrices into smaller particles with eventually accelerated erosion. However, the differences 
in these strategies follow from the mechanisms that cause the collapse of the matrix. Hydrogel 
forming agents show swelling and thus lead to the disintegration of the matrix, whereas the 
leaching of a hydrophilic porogen from a triglyceride matrix only decreases its mechanical 
stability. Collapse of the matrix will then be caused by mechanical stress, such as that 
occurring in vivo after subcutaneous implantation. On the other hand, these two strategies will 
result additionally in different sizes of the remaining matrix fragments. Resulting triglyceride 
particles will be smaller when hydrophilic porogens are used due to the higher amount of the 
excipient necessary to achieve a disintegration of the matrix. 
In order to investigate which of these strategies allows for a prolonged release from 
cylindrical lipid matrices and to get information on the ratios in which the respective excipient 
can be incorporated while still achieving release over several weeks, in vitro release 
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experiments were carried out. Thereby the number of animals needed for the following in 
vivo experiment on the erosion of triglyceride particles could be minimized. 
 
Results and discussion 
In vitro release of phospholipid-containing matrices 
For the in vitro tests the phospholipids DMPC and DPPC, the hydrogel forming agents 
agarose and sucrose were chosen as excipients. Since DSPC showed effects in in vivo 
investigations described above, phospholipids were used to investigate the strategy followed 
up with the amphiphilic molecules. Thus the three phosphatidyl-cholines DMPC, DPPC and 
DSPC were incorporated into glyceroltripalmitate cylindrical matrices by the emulsion 
method described in section 2.17 and [37]. As Figure 42 shows, the incorporation of any ratio 
of DMPC and DPPC (Figure 43) via the emulsion method led to complete release of the 
model drug within a few hours, as did the use of 25% and 50% DSPC (Figure 44). Only 
matrices with ratios of 5% and 10% of the phospholipid with the longest fatty acid chain were 
capable of sustained release over 10 days (Figure 44). 
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Figure 42: Influence of DMPC on the release profiles of pyranine from glyceroltripalmitate matrices prepared 
by using the emulsion method, cylinders contained 5% and 10% of the phospholipid; values 
represent mean ± SD (n=5). 
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Figure 43: Influence of DPPC on the release profiles of pyranine from glyceroltripalmitate matrices prepared 
by using the emulsion method; cylinders contained ratios of 5% to 50% of the phospholipid; values 
represent mean ± SD (n=5). 
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Figure 44: Influence of DSPC on the release profiles of pyranine from glyceroltripalmitate matrices prepared 
by using the emulsion method; cylinders contained ratios of 5% to 50% of the phospholipid; values 
represent mean ± SD (n=5). 
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These results indicate that the goal of prolonged release over several weeks from the 
triglyceride matrices cannot be achieved by using the emulsion method, because the influence 
of the erosion modifier on release properties of the matrices was too severe. Thus, a method 
was developed, which consists of two-steps. First, glyceroltripalmitate was loaded, as 
described in section 2.6, with the model drug. In a second step, the respective excipient was 
mixed with the drug loaded triglyceride powder. Thus, the influence of the excipients on the 
release was minimized, whereas their effect on the erosion of the lipid matrices should be 
maintained. For the drug loading it must be considered that the total drug content is decreased 
by incorporation of the modifying component, but can easily be adjusted by increasing the 
mass of the matrix.  
In the following, firstly DPPC and DMPC, the two phospholipids with shorter fatty acid 
chains of 16 and 14 C-atoms, respectively, were incorporated into glyceroltripalmitate 
matrices to investigate the strategy, followed up with the newly developed two-step method. 
In the case of DPPC, 5%, 10%, 25% and 50% of the phospholipid were investigated, whereas 
the ratio of 50% was not tested with DMPC. 
In Figures 45 and 46, release profiles of pyranine from lipid matrices containing 
phospholipid are shown. Regarding the results with DMPC, a prolongation of drug liberation 
of up to at least three days was observed for all ratios. This means an approximately 35 fold 
longer release period when using the two-step method, compared to matrices prepared with 
the emulsion method. The 5% DMPC containing matrices showed slightly slower release 
properties than the two other groups (Figure 45). For the phospholipid with the longer fatty 
acid chain yet more prolonged release periods were achieved and even with the very high 
ratio of 50% DPPC controlled release was realized (Figure 46). Drug release was completed 
in 10 days and 14 days, respectively, for the 50% and 25% DSPC containing matrices, 
whereas the two lower amounts of the erosion modifier, incorporated via the two-step method, 
led controlled release over a period of 7 weeks. 
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Figure 45: Release profiles of pyranine from glyceroltripalmitate matrices containing DMPC in ratios from 5% 
to 25%; cylinders were prepared by using the two-step method, data shown as a mean ± standard 
deviation (n=5). 
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Figure 46: Release profiles of pyranine from glyceroltripalmitate matrices containing DPPC in ratios from 5% 
to 50%; cylinders were prepared by using the two-step method, data shown as a mean ± standard 
deviation (n=5). 
Since the two-step method emerged as very useful to maintain sustained release properties 
of glyceroltripalmitate, it was used for all following in vitro investigations on possible erosion 
modifying components. 
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In vitro release of agarose-containing matrices 
In the next study, agarose was chosen as a hydrogel-forming and disintegrating agent. It 
was used in concentrations of 5%, 10% and 15%. Results for these experiments are shown in 
Figure 47. Due to high standard deviations of approximately 6.5%, which appeared for the 5% 
agarose containing group in this experiment, no significance in the differentiation of release 
profiles was observed. Nevertheless a tendency towards slower release with decreasing ratios 
of agarose was obvious. When 15% of the excipient was incorporated into the matrices, 
pyranine was liberated over 4 weeks, whereas the release period was prolonged to 6 and 7 
weeks, in case of 5% and 10% agarose containing matrices, respectively. 
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Figure 47: Release profile of pyranine from glyceroltripalmitate matrices containing agarose as an erosion 
modifier in different ratios; values are expressed as mean ± standard deviation (n=5).  
 
In vitro release of sucrose-containing matrices 
In addition to the phospholipids and agarose, sucrose was investigated for its in vitro 
suitability to serve as an erosion modifier for glyceroltripalmitate matrices, which would 
provide for the maintenance of the sustained release properties of the triglyceride. The 
followed strategy thereby was the formation of a network of sucrose crystals within the 
matrix, which should be leached out immediately at the beginning of the incubation or 
application, respectively. The resulting pores should decrease the stability of the matrix, lead 
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to the collapse of the cylinder into smaller fragments and thus accelerate the erosion. A 
schematic of this strategyis depicted in Figure 48. 
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Figure 48: Schematic of the strategy followed with the use of sucrose (gray regions) as an erosion modifier for 
drug loaded (orange regions) triglyceride matrices. 
For these investigations, different particle sizes of the porogen were tested. To this end, 
sucrose was sieved into fractions with different crystal sizes and incorporated into the lipid 
implants in ratios of 5%, 10%, 25% and 50%, respectively. In Table 9, the particle sizes of the 
sucrose and the abbreviations, which will be used in the following to succinctly describe the 
obtained fractions, are depicted. The particle sizes of the sucrose crystals incorporated into 
triglyceride matrices were in good agreement with the expected values, as SEM pictures 
showed (Figure 49). 
Table 9: Particle sizes of sucrose incorporated into glyceroltripalmitate matrices as pore-forming agents. 
fraction of sucrose particle size 
S25-45 25µm – 45µm 
S150-180 150µm - 180µm 
S250-355 250µm - 355µm 
S560-710 560µm - 710µm 
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Figure 1: SEM images of glyceroltripalmitate matrices in which 25% (w/w) sucrose from the S25-45-fraction 
was incorporated; the left picture shows the cylinder before and right picture after incubation of 12 
days in phosphate buffer, both 1000x. The sucrose crystals and resulting pores confirm particle sizes 
of the sieved fractions. 
In Figure 50, the effects of sucrose of varying particle size incorporated into 
glyceroltripalmitate matrices in ratios from 5% to 50% are shown. Regarding the ratio of 5% 
sucrose, no major differences in release profiles of pyranine from the lipid matrices of S25-45 
and S150-180 were observed (Figure 50). Regarding the larger sucrose fractions, pyranine 
was released almost similarly from matrices of the groups S250-355 and S560-710 over 
approximately 8 weeks, but after this time, liberation of the dye from cylinders containing 
sucrose of bigger crystal size occurred slower. 
When 10% sucrose was incorporated into the triglyceride matrices (Figure 51), release 
from the matrices modified with the biggest particle sizes showed nearly no alteration in 
comparison to that from 5% containing cylinders of the same group. In contrast, the three 
other sucrose fractions displayed an increase in the initial burst release of the model drug 
within the first day. Furthermore, liberation of the dye from matrices prepared with the S250-
355-fraction of sucrose aligned with that prepared with the two smaller particle sizes, which 
means a faster release compared to the 5% ratio or to the S560-710-group, respectively. 
Concerning the matrices containing 10% sucrose from the fractions S25-45 and S150-180, 
again no major differences in the shape of the resulting release profiles were observed. 
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Figure 50: Comparison of release profiles of pyranine from glyceroltripalmitate matrices containing 5% (w/w) 
sucrose crystals of different particle size as erosion modifier; data show mean ± SD (n=5). 
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Figure 51: Comparison of release profiles of pyranine from glyceroltripalmitate matrices containing 10% (w/w) 
sucrose crystals of different particle size as erosion modifier; data show mean ± SD (n=5). 
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Figure 52: Comparison of release profiles of pyranine from glyceroltripalmitate matrices containing 25% (w/w) 
sucrose crystals of different particle size as erosion modifier; data show mean ± SD (n=5). 
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Figure 53: Comparison of release profiles of pyranine from glyceroltripalmitate matrices containing 50% (w/w) 
sucrose crystals of different particle size as erosion modifier; data show mean ± SD (n=5),  
(please note the time scale of only 60 days). 
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The differences between the crystal size fractions were most obvious when the matrices 
were formulated with 25% sucrose (Figure 52). As expected, cylinders prepared with the 
smallest particle size of the erosion modifier showed fastest release of the dye (within 9 days), 
followed by matrices containing sucrose of the S150-180-fraction, which liberated the model 
drug over 4 weeks. Incorporation of 25% sucrose with particle sizes ranging from 250µm to 
355µm into lipid matrices led to a similar release profile compared to that obtained from the 
cylinders containing 10% of the erosion modifier of this fraction. Concomitantly, it was 
observed, that the ratio of 25% of the largest sucrose crystals led to a faster release than the 
two lower ratios. 
Regarding the release profiles resulting from an incorporation of 50% of sucrose into 
glyceroltripalmitate matrices (Figure 53), much faster liberation of the dye, and, with 
exception of the two smaller particle sizes, much larger standard deviations were observed. 
Matrices of the S25-45-group released the entire model drug within 2 days, whereas the 
release period from cylinders containing the S150-180-fraction of sucrose was three weeks. 
For the matrices prepared with the particle size fraction from 250µm to 355µm, the time of 
release of approximately 2 to 4 weeks could only be estimated with regard to continuously 
increasing mean value and standard deviations until day 56. No conclusions on the release 
period were drawn from results obtained from the S560-710-group, due to the very high 
standard deviations and incomplete release of the dye. Repetition of in vitro experiments on 
the latter two groups showed no alteration in the obtained release profiles. These problems, 
concerning the very high standard deviations, seemed to be due to difficulties during the 
incorporation of the erosion-modifying component, when both a high ratio and a big particle 
size, compared to the diameter of 2mm of the manufactured matrix, should be realized. 
The other results concerning the effects of incorporation of sucrose with varying particle 
size in different ratios into glyceroltripalmitate matrices are in good agreement with 
percolation theory. Since the goal of the incorporation of sucrose crystals into triglyceride 
matrices is the formation of a network, percolation theory can be applied to understand the 
results of the described investigations. Due to the preparation method of the matrices, in 
which the excipient was added to the dye-loaded lipid in a second step (see section 2.17), it 
must be considered, that an increase in the sucrose content did not lead to any change in the 
pyranine loading of the triglyceride. This means that alterations in release profiles from 
triglyceride matrices were caused by changes in the surface area, which was accessible for 
release. Since this surface area directly depended on the network formed by the hydrophilic 
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porogen, both the extension of the pore network as well as the time needed to leach out the 
porogen were of great importance for the resulting release profiles. 
Leuenberger et al. [166,167] described the existence of a so-called percolation threshold of 
a porogen within a matrix, below which no network will be formed. Figure 54 schematically 
shows the effect of an increased amount of sucrose particles incorporated into pyranine-
loaded glyceroltripalmitate matrices. With increasing amount of excipient (Figure 54b), the 
number of porogen particles that are localized on the surface of the matrix increases. Unlike 
porogen particles that are completely surrounded by triglyceride (Figure 54a), the particles on 
the surface are immediately leached out and thus lead to an increased surface area of the dye-
loaded triglyceride. A further increased ratio of the porogen results in the formation of a pore 
network (Figure 54c), thereby increasing the surface area of matrix fragments accessible for 
release and thus accelerating the release of the dye from the triglyceride matrix. 
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acceleration of pore-network formation
increased surface area accessible for release
a b c
 
Figure 54: Schematic for alteration of pore network formation caused by increasing the amount of sucrose 
crystals incorporated into pyranine-loaded glyceroltripalmitate matrices; a higher ratio of porogen 
also leads to increased number of particles localized on the surface of the matrix. 
Fernández-Herváz et al. examined the direct dependence of the percolation threshold on 
the particle size of the porogen [182]. They found lower percolation thresholds when the 
particle size of the porogen was decreased. This effect is schematically visualized for sucrose 
crystals incorporated into pyranine-loaded glyceroltripalmitate matrices in Figure 55. 
Decreasing the sucrose particle size leads to a higher surface area of the incorporated amount 
of the excipient. Thus again the amount of particles localized at the surface of the pyranine 
loaded matrix increases (Figure 55b) and with further decreasing of the sucrose particle size, a 
porogen network can be formed within the matrix (Figure 55c). 
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Figure 55: Schematic of sucrose particle size changing pore network formation within pyranine-loaded 
glyceroltripalmitate matrices. 
Release profiles of the pyranine from matrices, containing 5% sucrose can be explained by 
the number of particles localized at the surface of the matrices. In the case of the two smaller 
sucrose particle sizes (S25-45 and S150-180), at least a few particles should have had contact 
with the surface of the matrix. The percolation threshold of sucrose was not yet reached and 
thus no difference between these two groups was observed. The bigger sucrose particles 
might have been completely encapsulated into the triglyceride in the ratio of 5%. This would 
explain on the one hand why there was no difference in release profiles between the matrices 
prepared with the S250-355- and the S560-710-fractions of the sucrose, since the surface area 
of the dye-loaded glyceroltripalmitate, which was accessible for release, would have been 
comparable. On the other hand, the slower release of matrices from these groups compared to 
that of matrices prepared using the two smaller sucrose particles also becomes 
understandable. 
Increasing the amount of sucrose to 10% of the matrix lead to no major differences in the 
release profile compared to the matrices containing 5% of the excipientfor the largest sucrose 
particle size. This may again be explained by a complete encapsulation of the excipient, 
which consequently resulted in comparable surface areas for both ratios of sucrose. In the case 
of the S250-355-fraction, the ratio of 10% seemed to be enough that few particles were 
localized at the surface of the matrix, leading to a faster release compared to the lower ratio of 
5%. But since there was no difference observed between any release profiles of matrices 
prepared with 10% of the three smaller sucrose particle sizes, this amount did not seem 
sufficient to reach the percolation threshold. 
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When regarding the release profiles from matrices with ratios of 25% of the porogen, the 
fast release rates for S25-45 - and the S150-180- group show that the percolation threshold is 
reached for these two sucrose particle sizes at this ratio. Since the release profile of matrices 
containing 25% sucrose of the S250-355-fraction is comparable to that from 10% containing 
matrices, the percolation threshold is not yet reached for this particle sizes. The faster release 
of matrices containing 25% sucrose of the biggest particle size can be explained by the 
contact of the excipient to the surface of the matrix. 
Examination of the microstructure of the matrices after release confirmed the existence and 
the interconnectivity of a pore network for the two smaller sucrose particle sizes at the ratio of 
25%. Figure 56 shows the results observed by scanning electron microscopy. 
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Figure 56: SEM images of triglyceride matrices containing 25% of sucrose with varying crystal size after 
incubation; interconnectivity of the pores was observed  
a) 25µm - 45µm particle size of the erosion modifier, 1000x  
b) 150µm - 180µm particle size of the erosion modifier, 1000x.  
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As Figure 57 shows, no pore network, but contact of the sucrose particles to the surface of 
the matrices were observed by SEM for matrices containing 25% sucrose of the two bigger 
particle sizes. 
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Figure 57: SEM images of triglyceride matrices containing 25% of sucrose with varying crystal size after 
incubation 
c) 250µm - 355µm particle size of the erosion modifier, 40x  
d) 560µm - 710µm particle size of the erosion modifier, 40x. 
 
Summary 
These in vitro release experiments were carried out to characterize and quantify the effects 
of excipients on the release profile of triglyceride matrices. Substances should be found that 
allow for both the acceleration of the erosion and the prolonged controlled release from the 
lipid cylindrical matrices.  Therefore, two methods for the incorporation of the excipients 
were tested. With regard to the resulting very fast release from the modified 
glyceroltripalmitate matrices, the emulsion method was demonstrated to be unsuitable for the 
incorporation of any erosion modifier. Thus, a new two-step method was developed and 
established, which resulted in much longer release periods from the triglyceride matrices. 
Applying this method, the phospholipids DMPC and DPPC, the hydrogel-forming agent 
agarose, and the hydrophilic porogen sucrose were investigated for their use as erosion 
modifiers for lipid matrices. Matrices containing the phospholipid DMPC showed a release of 
the model drug within 3 days and this excipient was thus deemed unsuitable for use as an 
erosion modifier. When agarose or DPPC were incorporated in ratios of 5-15% and 5-50%, 
respectively, release periods from 2 to 7 weeks were achieved. Concerning the phospholipid 
DPPC, a dependence between the ratio of the modifying component and release period was 
visible, whereas matrices containing agarose showed no significant correlation between the 
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ratio of the disintegrating agent used and the duration of release. Thus, higher ratios of 
agarose may also be useful. 
To summarize the results obtained from the in vitro release investigations on sucrose, it 
can be said that release from triglyceride matrices containing this excipient depended on both 
the amount of sucrose incorporated into the matrix and the particle size of the excipient used. 
For sucrose, the dependence of release period extension on the used amount of the erosion 
modifier was more distinct using smaller particles sizes. Controlled release was realized for 
all crystal sizes and release periods of 2 to 15 weeks were achieved; only a ratio of 50% of the 
smallest sucrose particles led to a fast release within three days. 
To judge the suitability of a hydrophilic porogen, such as sucrose, as an erosion modifier, 
the percolation threshold is of great importance. This is the lowest concentration of sucrose 
within the matrix at which the formation of a network of the porogen can be observed. 
Sucrose ratios above the percolation threshold avoid encapsulation of the sucrose crystals 
within the dye-loaded triglyceride and thus enable the leaching of the excipient and 
consequently lead to a decrease of the mechanical stability of the matrix, which is the 
requirement for an acceleration of the in vivo erosion when the matrix is implanted and 
exposed to mechanical stress. The percolation threshold was reached for the two smaller 
particle sizes (25-45µm and 150-180µm) at a ratio of 25% of the excipient. 25% sucrose of 
the two bigger particle sizes (250-355µm and 560-710µm) was at least sufficient to avoid a 
complete encapsulation of the excipient. 
With regard to the high deviations, observed for the two biggest particle sizes (250µm-
355µm, 560µm-710µm), the ratios of 50% of these two sucrose fractions was considered not 
to be practicable for the preparation of cylinders with a diameter of only 2mm, but may be of 
good use, when larger implants should be prepared. 
In conclusion, the obtained results demonstrated that the phospholipid DPPC, the 
hydrogel-forming agent agarose and the hydrophilic porogen sucrose are suitable to modify 
the erosion of triglyceride matrices, since these three excipients allow for both a decrease in 
the stability of triglyceride matrices, which should result in faster erosion, and the 
maintenance of prolonged release from these matrices. 
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Introduction 
Since the in vitro experiments, presented in chapter 6, showed promising results 
concerning the possibility of prolonged, controlled release from triglyceride matrices 
containing a considerable amount of an excipient as erosion modifier, the next goal was to 
verify the hypothesis that the in vivo erosion of smaller lipid particles is faster than that of 
solid, macroscopic cylinders. In this in vivo study, glyceroltripalmitate microparticles and two 
groups of glyceroltripalmitate powders were implanted subcutaneously to immunocompetent 
NMRI-mice. In addition to the size effect of the lipid, the influence of triglyceride 
crystallinity was investigated by using two glyceroltripalmitate powder groups, which showed 
a high and low degree of crystallinity. To obtain information into whether small triglyceride 
particles undergo in vivo degradation, changes in the particle size of the samples were 
investigated over a period of 8 weeks. 
 
Microparticle and triglyceride-powder characterization 
This study was carried out for three groups of glyceroltripalmitate. Lipid microparticles 
were chosen, because of their smooth surface and very good reproducibility concerning 
particle size and manufacture. When spray-congealed, the microspheres show the instable β-
modification; therefore in addition lipid powders were investigated to clarify the influence of 
the modification of the triglyceride on its in vivo erosion. Concomitantly, it was considered 
that the crystallinity of a material may influence its in vivo erosion, and thus two groups with 
high and low degrees of crystallinity were investigated. Triglyceride powder, which was 
sterilized in solution by filtration with subsequent freezing in liquid nitrogen and freeze 
drying, showed low crystallinity, whereas lipid, which underwent hot air sterilization and 
afterwards was tempered for three days at 55°C showed high degree of crystallinity, similar to 
that of the bulk material. Results obtained by X-ray diffraction analysis are shown in Figures 
58-60. No major differences were observed between the bulk material (Figure 58) and the 
lipid powder sterilized by hot air and subsequently tempered for 3 days at 55°C (Figure 59). 
The peaks within the obtained graphics are distinct signs for a high degree of crystallinity. For 
the freeze-dried glyceroltripalmitate (Figure 60) peak formation was much less distinct, which 
indicates a lower degree of crystallinity compared to the heat sterilized varient. 
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Figure 58: Wide-angle X-ray diffractogram of glyceroltripalmitate bulk material; clearly visible peaks show 
high degree of crystallinity 
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Figure 59: Wide-angle X-ray diffractogram of glyceroltripalmitate; material underwent sterilization for 2h at 
110°C and tempering (3days at 55°C), peaks show high degree of crystallinity. 
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Figure 60: Wide-angle X-ray diffractogram of glyceroltripalmitate; material was dissolved in THF, filtrated, 
frozen in liquid nitrogen and freeze dried, absence of peaks, respectively less distinctive peaks show 
low degree of crystallinity 
Particle sizes of the investigated lipid samples were determined with laser diffractometry, 
without the application of ultrasonication. Results are shown in Figure 61. For lipid 
microparticles a mean diameter of 176µm was determined, whereas both lipid powders 
showed a multimodal distribution with peaks at particle sizes of 10µm to 20µm and 
approximately 100µm. All observed particle sizes were confirmed by SEM analysis (Figures 
62,63). In the case of the heat-sterilized and freeze-dried triglyceride, the particle size 
distributions indicate the formation of aggregates, which was also confirmed by results 
obtained from SEM analysis 63). 
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Figure 61: Particle size distribution of lipid microparticles ( ) and freeze dried (- -) and heat sterilized (▪▪) 
glyceroltripalmitate powders for in vivo erosion study, determined by laser diffractometry. 
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Figure 62: SEM image of glyceroltripalmitate microparticles prior to in vivo investigation (50x). 
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Figure 63: SEM images of freeze-dried (left) and heat-sterilized and tempered (right) triglyceride powders prior 
to in vivo investigation, both 200x. 
For the investigation of the particle size of the glyceroltripalmitate samples and its 
alteration during the course of the study, histological sections were examined and holes 
stemming from the microparticles and the triglyceride powder were measured by light 
microscopy as described in section 2.21. Since the deformation of the holes, which was 
observed for the microsphere group, was in similar direction in every investigated slice 
(Figures 3,65), it may not have arisen during in vivo study, but could also be an artifact of the 
sectioning process. This would also be confirmed by the absolutely round shape of the 
microparticles prior to the in vivo investigation observed by SEM (Figure 62). 
 
In vivo erosion study 
As Figure 63 shows, the two lipid powders were not of spherical shape. Since the 
described estimator for the real particle diameter (see equation (1) in section 2.21) is only 
valid for spherical particles, quantitative results can only be reported for the lipid 
microspheres in our in vivo experiment. For the lipid powder groups, only qualitative 
conclusions on the degradation were drawn, because of their irregurar shape. 
Concerning the freeze-dried triglyceride powder at day 7, larger and smaller particles were 
seen in histological investigations (Figure 64a), which can be explained by the determined 
particle size distribution (Figure 61) and SEM results for this group (Figure 63). Days 17 
(data not shown) and 28 showed comparable results, which can be distinguished from those 
from day 7 by a decreasing number of the lipid powder particles and fewer particles of bigger 
size (Figures 64b,c). 42 days after implantation, no particles were found in any section of all 4 
mice, whereas at day 56 in one single slide of one animal particles were seen (Figure 64d), 
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which had a decrease in size compared to the other excision time points during the study 
(Figures 64a-c). Since only in one mouse, out of four, particles were found after 8 weeks and 
these particles were very small, it could be considered that the lipid powder seemed to be 
compeletly degraded during the in vivo study. 
   
   
Figure 64: Light microscopy pictures of histological sections of the freeze-dried glyceroltripalmitate powder at 
different time points of the study, single arrows mark lipid powder particles, all pictures HE stained, 
a) histological section of a sample excised at day 7, 100x  
b) histological section of a sample excised at day 28, 100x  
c) histological section of a sample excised at day 28, 400x  
d) picture of the only particle containing histological section in samples excised at day 56, 400x; 
double arrows mark adipocytes at the interface between adipose tissue and other tissue containing 
the lipid powder particles. 
The results for the heat-sterilized and tempered glyceroltripalmitate powder were almost 
identical with these obtained for the freeze-dried lipid powder. Large particles were observed 
after 7 days, but their number decreased with time. After 42 and 56 days, no particles were 
found in any mouse, which indicated the complete degradation of the triglyceride powder. 
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Concerning the group of lipid microparticles, the implanted samples were not completely 
degraded during the investigated period of 8 weeks. At day 56, every examined animal 
displayed a considerable number of microspheres (Figure 65). 
 
Figure 65: Light microscopy image of a histological section of lipid microparticles containing the tissue sample 
excised at day 56, HE stained, 100x. 
The determination of the lipid microparticle diameters and the subsequent application of 
the estimator (see equation (1) in chapter 2) made it possible to visualize changes in particle 
size occurring during the course of the in vivo study. In Figure 66, the particle sizes of the 
microspheres, which were observed for each excision time point, are depicted. 
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Figure 66: Changes in size of glyceroltripalmitate microparticles over 8 weeks in vivo; values calculated from 
the measured diameters by use of the estimator depicted in equation (1) (see section 2.21) 
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Although the lipid microparticles were not completely eroded within the duration of the in 
vivo study of 8 weeks, a trend is visible. The decrease in the estimated mean diameter from 
approximately 160µm at day 7 to 100 µm at day 56 suggests that the lipid was not inert in 
vivo, but seemed to be degraded with time. To investigate whether complete erosion of the 
triglyceride microparticles occurs, a long term in vivo study has to be carried out, to confirm 
these early results. 
The faster degradation of the triglyceride powder compared to the microparticles can be 
explained by two factors. Firstly, the microstructure, examined by SEM, indicated a much 
higher apparent density of the microparticles (Figure 67) compared to the two lipid powders 
(Figure 68). Glyceroltripalmitate microparticles appear to be much more compact than the 
lipid powders, as is visible throughout the more loose-packed crystal structure of the 
triglyceride powders. Therefore, samples of the microparticle group might have been more 
stable against in vivo degradation. Consequently, this led to longer erosion times for the 
glyceroltripalmitate microparticles compared to the powder groups and confirmed the in vivo 
findings. 
 
10µm
 
Figure 67: SEM images of lipid microparticles prepared by spray congealing for in vivo erosion study, 1000x, 
dense structure and high crystallinity were seen. 
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Figure 68: SEM images of lipid powders prepared by using variable sterilization methods for in vivo erosion 
study, both 1000x  
a) heat sterilized triglyceride powder, arrangement of glyceroltripalmitate crystals revealed less 
dense compared to the microparticles  
b) freeze-dried triglyceride powder, glyceroltripalmitate crystal formation was not loose-packed. 
Secondly, the lipid microparticles were larger in size (Figure 62) compared to the two 
glyceroltripalmitate powder groups at the beginning of the study. To confirm the hypothesis 
of these in vivo investigations, which was the direct dependence of the in vivo erosion time of 
the triglyceride on its particle size, additional investigations that are long enough to allow for 
the complete erosion of the triglyceride powers will be necessary. However, first positive 
results were obtained from these investigations. 
 
Summary 
This in vivo study was carried out to investigate the hypothesis of a correlation between 
the triglyceride particle size and the in vivo erosion time of the material. Concomitantly, the 
influence of the degree of crystallinity on the in vivo erosion was examined. Therefore 
glyceroltripalmitate microparticles and two groups of glyceroltripalmitate powders with a 
high and low degree of crystallinity, respectively, were investigated in vivo. The results 
showed the degradation of both types of implanted triglyceride powders. No differences in the 
in vivo erosion were observed due to the varying degree of crystallinity of the triglyceride 
powders. Due to the non-spherical shape of the glyceroltripalmitate powder material, no 
quantitative results were obtained, but only qualitative conclusions were drawn. After 56 
days, the glyceroltripalmitate powders disappeared. 
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Although the lipid microparticles were not completely eroded by the end of the 56 day 
study period, the decreasing diameter clearly indicated that degradation processes were 
occurring in vivo. These results gave the first positive hints towards the investigated 
hypothesis of a correlation between the particle size of the triglyceride and the in vivo erosion 
time. 
Chapter 7  In vivo Investigation on the Erosion of Triglyceride Particles 
 -112-  
Chapter 8  Programmable Implants – From Pulsatile to Controlled Release 
 -113-  
Chapter 8 
Programmable Implants  
– 
From Pulsatile to Controlled Release 
 
Chapter 8  Programmable Implants – From Pulsatile to Controlled Release 
 -114-  
Introduction 
In recent years “intelligent” drug delivery systems, such as microchip devices, have been 
developed [183,184]. The advantage of such systems is their ability to release a plethora of 
individual doses of one or even several substances from a multitude of drug reservoirs. Due to 
the pulsatile release of individual doses, any desirable release profile can be ‘generated’ by 
repetitively releasing dose after dose. According to the literature, ‘pulsatile drug delivery’ 
denotes the release of drugs, peptides or proteins with high rates within a narrow time interval 
[185]. Such delivery systems are classified as single- or multiple-pulse systems. They are 
frequently based on polymeric materials that release a drug almost instantly [186-187]. Many 
different delivery systems have been developed, such as microchip based devices [183,189] as 
well as matrices with concentric layers of biodegradable polymer [190,191].  
A disadvantage of these systems, however, is that too many pulses would be needed to 
create a release profile that stretches over extended periods of time, such as several weeks. To 
overcome this limitation, programmable implants consisting of a drug-loaded polyanhydride 
core embedded in a drug-free bulk eroding polymer mantle were developed [39]. This system 
enables a delayed onset of release adjustable by the choice of the mantle material followed by 
a pulsatile release. However, due to the fast eroding polyanhydride core it was not possible to 
release drug over an extended time period from these implants. Therefore, in this study we 
tested different lipophilic core materials with regard to their ability to control drug release 
[39,192]. In Figure 69 a a comparison of the intended release profiles of this new generation 
of programmable implants is shown. 
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Figure 69: Comparison of release profiles resulting from programmable implants with polyanhydride and 
triglyceride cores, respectively. 
This controlled prolonged release from the prepared systems may be of great benefit when 
highly potent substances, for example growth factors [193,194], cytokines [195,196] or anti-
cancer drugs [197] have to be administered. Such drugs would rapidly exceed therapeutic 
concentrations during pulsatile release. Concomitantly, controlled prolonged release may be 
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desirable for an intracranial treatment, since, for example, neurodegenerative diseases or brain 
tumors frequently require long-term therapy [34,198,199]. 
The goal of this study was to design programmable implants with a reproducible onset of 
release and a controlled release once the liberation of the drug has started. Different core and 
mantle materials were tested for this purpose. Finally, a mathematical model based on 
convolution theory [159-162] was developed, which allows for the prediction of release 
profiles, when the release from the core material and the properties of the mantle material are 
known. 
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Results 
In vitro release 
First, the release of pyranine from the lipid core matrices without the polymer mantle was 
investigated (Figure 70). Cholesterol showed the fastest release within 1.5 hours, whereas 
glyceroltrilaurate (C12) and glyceroltristearate (C18) released the incorporated dye over a 
period of 14 days. The triglycerides with the longer fatty acid chains showed continuous 
release of the model compound over approximately 10 weeks for glyceroltripalmitate (C16) 
and 16 weeks for glyceroltrimyristate (C14). 
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Figure 70: In vitro release profiles of pyranine as model drug from variable lipophilic core materials, for 
different triglycerides the number of C-atoms of the fatty acid chains is given, data show mean 
± standard deviation (n=5). 
The first steps to embed the cores into a bulk eroding polymer mantle made of PLGA17 
were carried out using the manufacturing procedure with the heat treatment at 110°C. 
Unfortunately, the resulting implants prematurely released their contents in an unpredictable 
manner, due to incomplete pore closure (data not shown). In addition to this irreproducible 
onset of release, DSC investigations showed that the heating step might additionally cause an 
alteration of the modification of the crystalline lipid core materials (data not shown). 
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A perfectly delayed release with a reproducible onset of all investigated core and mantle 
materials (Figures 71-73) was obtained by applying a second compression step to the finished 
implants at temperatures above the glass transition temperature of the respective mantle 
polymer (see Figure 6 in chapter 2, section 2.22). 
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Figure 71: In vitro release from programmable implants with different core materials and PLGA10 as polymeric 
mantle material, for different triglycerides the number of C-atoms of the fatty acid chains is given, 
values are expressed as mean ± standard deviation (n=4). 
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Figure 72: In vitro release from programmable implants with different core materials and PLGA17 as polymeric 
mantle material, for different triglycerides the number of C-atoms of the fatty acid chains is given, 
values are expressed as mean ± standard deviation (n=4). 
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Figure 73: In vitro release from programmable implants with different core materials and PLA30 as polymeric 
mantle material, for different triglycerides the number of C-atoms of the fatty acid chains is given, 
values are expressed as mean ± standard deviation (n=3). 
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For all investigated groups, reproducible onset of the release after the degradation of the 
polymer mantle was achieved (Figures 74-76). Delay times were 8 days for PLGA10 (Figure 
74), 21 days for PLGA17 (Figure 75) and 83 days when the PLA30 was used as mantle 
material (Figure 76) Concomitantly, the desired prolonged release from the programmable 
implants over periods from 2 weeks (glyceroltrilaurate (C12) and glyceroltristearate (C18)) up 
to several months (glyceroltrimyristate (C14) glyceroltripalmitate (C16)) was achieved. 
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Figure 74: Delay times for the onset of release observed for programmable implants, prepared with varying 
core materials and with PLGA10 as mantle material, data represent mean ± standard deviation, 
++ indicates statistical significance with p<0.01, + indicates statistical significance with p<0.05 
(n=4). 
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Figure 75: Delay times for the onset of release observed for programmable implants, prepared with varying 
core materials and PLGA17 as mantle material, data represent mean ± standard deviation, 
++ indicates statistical significance with p<0.01, + indicates statistical significance with p<0.05 
(n=4). 
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Figure 76: Delay times for the onset of release observed for programmable implants, prepared with varying 
core materials and with PLA30 as mantle material, data represent mean ± standard deviation, 
++ indicates statistical significance with p<0.01, + indicates statistical significance with p<0.05 
(n=3). 
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Mathematical modeling 
For the design of programmable implants, it would be desirable to be able to predict the 
resulting release profile when a core with known release properties is embedded into a 
polymer mantle. Thus, a convolution model was applied to investigate whether a sensible 
prediction is possible. For the above-described mathematical modeling, the release of 
pyranine from a cholesterol core matrix was used as unit impulse function for the matrix 
materials PLGA10 and PLGA17. For the investigations carried out with PLA30 as polymeric 
mantle material, release data from polyanhydride cores gathered by Vogelhuber et al. [39] 
were used as the unit impulse function. Both core materials showed complete release of the 
incorporated pyranine within one day and can thus be used as unit impulse functions. The 
release profiles are shown in Figure 77. 
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Figure 77: Used unit impulse functions for mathematical modeling, values are expressed as mean ± SD (n=5); 
Release from cholesterol cores was used for PLGA10 and PLGA17;  
Release from polyanhydride cores [39] was used for PLA30. 
In Figures 78-87 results of predicted release curves are compared with the experimental 
release data. When glyceroltrilaurate (C12) core matrices were embedded into a PLGA10 
mantle (Figure 78), a slightly slower release was determined experimentally, compared to the 
theoretical profiles. For glyceroltristearate (C18) cores embedded into this polymeric mantle 
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material, the same effect was observed (Figure 79). Again in vitro release occurred slightly 
slower than predicted by the convolution model. 
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Figure 78: Release profiles from programmable implants, prepared with PLGA10 as mantle material and 
glyceroltrilaurate (C12) as core material;  
(■): values of experimental release data are expressed as mean ± SD (n=5),  
(–): theoretical release calculated with mathematical model of convolution theory by the use of 
release data from cholesterol cores as unit impulse function. 
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Figure 79: Release profiles from programmable implants, prepared with PLGA10 as mantle material and 
glyceroltristearate (C18) as core material; , 
(■): values of experimental release data are expressed as mean ± SD (n=4),  
(–): theoretical release calculated with mathematical model of convolution theory by the use of 
release data from cholesterol cores as unit impulse function. 
Chapter 8  Programmable Implants – From Pulsatile to Controlled Release 
 -123-  
Differences between theoretical and experimental release profiles were also observed for 
the programmable implants prepared with glyceroltrimyristate (C14) as core material and 
PLGA10 as polymer mantle (Figure 80 In this case, programmable implants released the 
model drug faster than predicted by the model. Deviations between the profiles were higher in 
the first period of release, but disappeared afterwards. Only minimal differences were 
observed between theoretically predicted and experimentally determined release profiles after 
6-7 weeks and, as could have been expected for the end of the release experiment, good 
agreement was seen from day 70 to day 112. Figure 81 shows similar results for 
glyceroltripalmitate (C16) cores. The again visible but less distinctive differences between 
predicted and in vitro determined release profiles of pyranine from the programmable 
implants were only visible within the first period of release, but not from day 35 to day 77, 
which was here the last time point of the experiment. 
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Figure 80: Release profiles from programmable implants, prepared with PLGA10 as mantle material and 
glyceroltrimyristate (C14) as core material;  
(■): values of experimental release data are expressed as mean ± SD (n=5),  
(–): theoretical release calculated with mathematical model of convolution theory by the use of 
release data from cholesterol cores as unit impulse function. 
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Figure 81: Release profiles from programmable implants, prepared with PLGA10 as mantle material and 
glyceroltripalmitate (C16) as core material;  
(■): values of experimental release data are expressed as mean ± SD (n=4),  
(–): theoretical release calculated with mathematical model of convolution theory by the use of 
release data from cholesterol cores as unit impulse function. 
Concerning the results observed for programmable implants made with PLGA17 as a 
polymeric mantle material, comparable findings were obtained for the two faster releasing 
core materials glyceroltrilaurate (C12) and glyceroltristearate (C18) as seen for PLGA10. In 
these groups again the mathematically predicted release was slightly faster than 
experimentally determined (Figures 82,83). For the slower releasing core materials, 
glyceroltrimyristate (C14) and glyceroltrilaurate (C12), very good correlations between the 
theoretically predicted release curves and the experimental data were achieved (Figures 
84,85), when these matrix materials were embedded into a mantle of PLGA17. 
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Figure 82: Release profiles from programmable implants, prepared with PLGA17 as mantle material and 
glyceroltrilaurate (C12) as core material;  
(■): values of experimental release data are expressed as mean ± SD (n=4),  
(–): theoretical release calculated with mathematical model of convolution theory by the use of 
release data from cholesterol cores as unit impulse function. 
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Figure 83: Release profiles from programmable implants, prepared with PLGA17 as mantle material and 
glyceroltristearate (C18) as core material;  
(■): values of experimental release data are expressed as mean ± SD (n=4),  
(–): theoretical release calculated with mathematical model of convolution theory by the use of 
release data from cholesterol cores as unit impulse function. 
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Figure 84: Release profiles from programmable implants, prepared with PLGA17 as mantle material and 
glyceroltrimyristate (C14) as core material;  
(■): values of experimental release data are expressed as mean ± SD (n=5),  
(–): theoretical release calculated with mathematical model of convolution theory by the use of 
release data from cholesterol cores as unit impulse function. 
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Figure 85: Release profiles from programmable implants, prepared with PLGA17 as mantle material and 
glyceroltripalmitate (C16) as core material;  
(■): values of experimental release data are expressed as mean ± SD (n=5),  
(–): theoretical release calculated with mathematical model of convolution theory by the use of 
release data from cholesterol cores as unit impulse function. 
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When the slowest eroding mantle material (PLA30) was used for the embedding of 
glyceroltrimyristate (C14) and glyceroltripalmitate (C16), again a faster theoretically 
predicted release was observed compared to the in vitro findings (Figures 86,87). 
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Figure 86: Release profiles from programmable implants, prepared with PLA30 as mantle material and 
glyceroltrimyristate (C14) as core material;  
(■): values of experimental release data are expressed as mean ± SD (n=3),  
(–): theoretical release calculated with mathematical model of convolution theory by the use of 
release data from polyanhydride cores as unit impulse function. 
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Figure 87: Release profiles from programmable implants, prepared with PLA30 as mantle material and 
glyceroltripalmitate (C16) as core material;  
(■): values of experimental release data are expressed as mean ± SD (n=3),  
(–): theoretical release calculated with mathematical model of convolution theory by the use of 
release data from polyanhydride cores as unit impulse function. 
 
Discussion 
In vitro release 
All three of the mantle materials tested produced programmable implants with a 
reproducible onset of release. This confirms the suitability of the preparation method with a 
second compression step at a temperature above the Tg of the respective mantle material to 
completely close pores, which occur within the polymer mantle. Additionally, the goal of the 
controlled release after the onset was achieved. Programmable implants containing 
glyceroltrilaurate (C12) or glyceroltristearate (C18) released the model drug over two weeks, 
whereas programmable implants prepared with glyceroltrimyristate (C14) or 
glyceroltripalmitate (C16) as matrix materials showed release periods extending over months 
(Figures 71-73). This is identical to the results for non-embedded core matrices (Figure 70). 
Vogelhuber et al. reported shorter delay times before the start of release for the three 
polymer materials (see bars of polyanhydride cores in Figures 74-76), which is due to the 
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different core materials used [39]. The degradation of a polyanhydride core, as it was used 
previously [39] most likely led to an acidic microclimate, which worked as a catalyst and thus 
accelerated the degradation of the mantle polymer. This effect did not occur when lipid core 
materials were used and thus the delay time for the onset of the programmable implants 
increased significantly in most cases. Only for the group of glyceroltripalmitate cores 
embedded into PLGA10 as mantle material, significance was not reached due to relatively 
high standard deviations. 
 
Mathematical modeling 
Matrices made by embedding glyceroltrilaurate (C12) and glyceroltristearate (C18) in 
PLGA10 displayed slower release profiles experimentally than was predicted using the 
mathematical modeling (Figures 78,79). This can be explained by the percentage of dye 
released in the experiment from glyceroltrilaurate and glyceroltristearate core matrices into 
the polymer mantle during the delay time of the programmable implants and the fact that the 
onset day of release from programmable implants was chosen as starting point for the 
mathematical modeling, due to the above mentioned reasons. Regarding the algorithm 
depicted in equation (11), the consequence for the theoretical prediction can be briefly 
described as follows: The calculated amount of dye released from the core matrix until the 
onset (=I0 in equation (11)) is treated in the mathematical model as if it was released in the 
experiment at day 1 (=I0 of the unit impulse function). Thus, for example when a core matrix 
would show complete release of the model drug within 7 days or less experimentally, the 
predicted release profile for the programmable implants would always be exactly the same as 
it was obtained for the unit impulse function. But since release from the glyceroltrilaurate 
(C12) and glyceroltristearate (C18) core matrices in fact occurred over a longer period of time 
(Figure 70), less diffusion of the model drug within the polymer mantle occurred during the 
delay time and thus explaining the slower in vitro release from the programmable implants 
compared to the theoretical prediction.  
 Release of the core matrices had reached approximately 87% at day 7 in the case of 
glyceroltrilaurate (C12) and glyceroltristearate (C18) core matrices released 91% of the dye 
within the first 7 days (Figure 70), which was the delay time for PLGA10. Thus, differences 
between the two release profiles were slightly higher in case of the C18 triglyceride compared 
to glyceroltrilaurate (C12). 
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But despite the alignment of the calculation method, the modeling resulted in a rather 
acceptable agreement between predicted and experimentally observed release curves. 
The deviations in the first release period when glyceroltrimyristate (C14) was used as core 
material and PLGA10 served as polymer mantle (Figure 80), may be explained by the 
relatively unsteady onset of release in this group, which was observed by slightly higher 
standard deviations, compared to the other investigated groups (Figures 74-76). Since a 
slightly unsteady onset of release was also observed for glyceroltripalmitate cores (Figure 74), 
the deviations in the early period after the onset (Figure 81) may be explained. Considering 
these results, a rather acceptable agreement between theory and experiment was observed for 
PLGA10 as mantle material. 
 
Programmable implants made with PLGA17 as polymeric mantle material and the two 
faster releasing core materials, glyceroltrilaurate and glyceroltristearate, lead to slower release 
of the implants than predicted (Figures 82,83), due to the above described reasons. 
Nevertheless, when glyceroltrilaurate was used as core material, an acceptable prediction was 
obtained by convolution and in the glyceroltristearate group two release profiles even showed 
rather good agreement. Concerning the slower releasing core materials glyceroltrimyristate 
and glyceroltrilaurate, measured release profiles fitted nearly perfectly into the 
mathematically modeled prediction of release. 
 
Concerning PLA30, release of pyranine from glyceroltrimyristate cores was approximately 
85% at day 83 (Figure 70), which was the onset of the release from programmable implants 
with this mantle material. Glyceroltripalmitate cores show a complete release of 100% of the 
dye within an even shorter time period of 70 days (Figure 70). However, the observed 
deviations between predicted and determined release profiles, which can be explained as 
aforementioned, were only minute and convolution again resulted in acceptable agreement 
between theory and experiment. 
These results showed that it is possible to make sensible predictions for the release from 
programmable implants with one of the three investigated polymeric mantle materials when 
release from the core material is known. Concomitantly, convolution results calculated for 
PLA30 were obtained by using data from a polyanhydride core as unit impulse function. These 
release data for the pulsatile releasing core material were detailed by Vogelhuber 4 years ago 
[39], but, nevertheless, a rather good fitting of the theoretical release curves and the 
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experimental profiles obtained for investigations on triglycerides was observed. This 
additionally demonstrated the suitability of convolution for the modeling of theoretical release 
profiles from programmable implants. The prediction of the expected release profile is of 
great benefit for the design of programmable implants with desired release properties. When 
release from a core matrix is known, convolution alleviates the need for further in vitro 
release experiments with programmable implants, due to the possibility to sensibly predict the 
expected resulting release profile. 
 
Summary 
The investigated programmable implants can be described briefly as a drug loaded core 
matrix embedded into a drug free bulk eroding polymer mantle, which inhibits drug release 
until its erosion is completed. The aim of this study was to develop a new generation of 
programmable implants, which allow for prolonged release, since the devices developed by 
Vogelhuber et al. [39] were limited to pulsatile liberation of incorporated compounds. The 
goal of controlled release after the onset was realized by using triglycerides as core materials 
and release periods from 2 weeks up to several months were achieved. The delay time for the 
release from the programmable implants was varied with the polymeric mantle material from 
8 to 83 days. Concomitantly, it was shown that applying a model based on convolution leads 
to a sensible prediction of the release of a drug from the programmable implants when release 
rate from the core material is known. This facilitates the design of programmable implants 
and offers a powerful tool for the adjustment of the resulting drug release to desired profiles. 
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1. Summary 
Implants are one of the most important class of devices for the controlled parenteral release 
of drugs. Therefore, many materials have been investigated for potential use as a matrix 
material for implantable devices (chapter 1). Investigation of crucial parameters during the 
manufacturing procedures of such an implant as well as the identification of mechanisms that 
dominate the release of drugs from the chosen material are essential for the design of a 
controlled release device. Additionally, the in vivo compatibility and erosion behavior of a 
material play a pivotal role in the suitability of a material for parenteral application. This work 
focused on lipid materials, primarily triglycerides, for the design of parenterally applicable 
controlled release implants. 
Since triglycerides and other lipid materials are currently being investigated as alternatives 
to polymeric materials for the delivery of proteins and peptides [118,153,154], the first study 
served to investigate if release profiles of the two model drugs insulin and somatostatin from 
triglyceride matrices can be determined directly from the release medium. Therefore, their 
stability within the release medium, which is essential for a determination of correct 
controlled release profiles, was investigated (chapter 3). Both model drugs underwent distinct 
degradation when incubated in release medium over 5 weeks and the extent of degradation 
was quantified to 35% for insulin and even 65% for somatostatin. The resulting degradation 
products were identified as a deamidation product of somatostatin and the non-covalent dimer 
of insulin. With these experiments, the necessity of extraction of both model drugs from 
glyceroltripalmitate matrices for the characterization of long-term in vitro release was shown. 
Thereby, not only could the residue content be determined, but also the investigation of 
protein and peptide stability within the matrices was facilitated (chapter 3). For the use in 
further investigations [153,154], a liquid/liquid extraction method developed by Lucke et al. 
(see section 2.5 in chapter 3 and [141]) was optimized. Concomitantly, a solid/liquid 
extraction method was newly developed to avoid liquid phase separation and thus protect 
proteins and peptides from degradation during the extraction process [141]. This will be 
useful for stability studies of protein and peptide model drugs within the triglyceride matrix 
material. Extraction yields of 94.5% +/-0.8% and 91.3% +/-5.1% were realized for 
somatostatin and insulin, respectively, using the newly developed method. 
After these experiments on protein and peptide model drugs, the triglyceride material and 
its cylindrical matrices were characterized to facilitate the design of the desired controlled 
release device for parenteral drug delivery. Since the following in vitro investigations on the 
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basic characteristics of triglyceride matrices were mechanistic studies, it was decided that the 
use of proteins and peptides would have some disadvantages, such as the necessity of re-
extraction, lower sensitivity of analytical methods, or possibly occurring degradation 
processes. Thus, in the following experiments fluorescent dyes were used as model drugs. 
The first objective towards the characterization of triglycerides for the design of controlled 
release matrices was the identification of crucial parameters during the manufacturing 
procedure and to investigate the extension of their influence on the resulting release profiles 
(chapter 4). To this end, glyceroltripalmitate was loaded with pyranine, a highly water 
soluble fluorescent dye. Subsequently, cylindrical matrices were manufactured under varying 
conditions. The investigated parameters for the preparation of the implants were the drug 
distribution within the matrices, dye loading, compression force and geometry of the 
cylindrical implants (chapter 4). Improving the distribution of the dye within the cylindrical 
implants led to an increase of the controlled release time period. Varying the pyranine content 
within the matrix revealed drug loading as one of the most important parameters concerning 
the expected release profiles. Release properties varied from nearly burst (33% drug loading) 
to controlled release over 17 weeks (10% drug loading) to a very slow release of only about 
13% of the total loaded drug over the investigated time period of 17 weeks (1% drug loading). 
Compression force was shown as well to have severe influence on release profiles when 
varied at lower values, but was less decisive when higher forces were applied. This indicated 
the existence of a threshold for this parameter, which was reached when compressing the 
implants at 250N. Two parameters were investigated for cylinder geometry. Varying the 
implant height resulted in no significant influence on release profiles, whereas a decrease in 
implant diameter accelerated the liberation of the dye. This allows for the adjustment of the 
dose desired for application without alteration of the release profile.  
 After the preparation procedure of the triglyceride matrices was characterized, concomitant 
investigations on release mechanisms and properties of model drugs influencing the release 
were carried out (chapter 4). Three crucial parameters were identified: (i) An acceleration of 
the release from the matrices was observed when hydrophilicity of the model drug was 
increased. (ii) Water uptake into the matrices was proved by fluorescence microscopy after 
incubation of blank triglyceride cylindrical matrices in a solution of fluorescein-di-sodium 
salt. This indicated clearly the formation of pores and the possibility of diffusion of the 
incorporated drugs to the surface, where release occurs subsequently. Pore formation directly 
depended on the particle size of the glyceroltripalmitate used for the preparation of the lipid 
matrices. (iii) In an in vitro release experiment of fluorescein-di-sodium salt from 
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glyceroltripalmitate matrices, carried out with release media of increased osmotic pressure, 
osmosis was shown as well to be involved in the release process of drugs from triglyceride 
matrices. This indicated that liberation of a drug from glyceroltripalmitate matrices was not 
purely diffusion-controlled. 
Since the in vitro properties of triglyceride matrices were well characterized at this point, 
the in vivo properties of the material were investigated subsequently. Two studies on the in 
vivo biocompatibility of glyceroltripalmitate and cholesterol were carried out (chapter 5). 
Concomitantly, the long term in vivo stability, which is a prerequisite for controlled 
prolonged release, was investigated. In these two experiments both in vivo biocompatibility as 
well as long term in vivo stability of gloceroltripalmitate and cholesterol was shown. Neither 
significant inflammatory response nor cytotoxic reactions were observed for any of the two 
materials. The triglyceride implants were stable and maintained their cylindrical shape over 
two months. Furthermore, the ability to influence the in vivo erosion of glyceroltripalmitate 
by the incorporation of the phospholipid DSPC was shown in these in vivo experiments 
(chapter 5). 
Due to the in vivo stability of the triglyceride, the erosion behavior of the material was 
subsequently investigated. Firstly, in vitro experiments on the suitability of several excipients 
as modifying components for the triglyceride erosion were carried out (chapter 6). The 
strategy taken can briefly be described as a decrease in matrix stability, which would lead to 
the disintegration of the lipid matrix when it is exposed to mechanical stress, as it occurs in 
vivo after subcutaneous implantation. In these experiments, the phospholipids DMPC and 
DPPC, the hydrogel-forming agent agarose, and varying crystal sizes of the hydrophilic 
porogen sucrose were investigated for their ability to maintain the controlled release 
properties of glyceroltripalmitate when incorporated in considerable amounts into the 
triglyceride matrices. For the incorporation of the modifying components, two methods were 
tested. The emulsion method, previously described [37] for drug loading, could not be applied 
for the incorporation of any erosion modifier, due to the resulting very fast release of the 
model drug pyranine from the glyceroltripalmitate matrices within a few hours. Consequently, 
a two-step method was developed for this purpose (chapter 6) with which the suitability of 
sucrose, agarose and DPPC as erosion modifiers for glyceroltripalmitate matrices was proven 
in vitro (chapter 6). When agarose or DPPC were incorporated in ratios of 5-15% and 5-50%, 
respectively, release periods from 2 to 7 weeks were achieved. Release from triglyceride 
matrices containing sucrose depended on both the amount of sucrose incorporated into the 
matrix and the particle size of the excipient used. Controlled release was realized for all 
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crystal sizes and release periods of 2 to 15 weeks were achieved; only a ratio of 50% of the 
smallest sucrose particles led to a fast release within three days. 
With regards to these promising in vitro results, the hypothesis for the in vivo use of 
erosion modifiers for triglyceride matrices, which is the correlation between the in vivo 
erosion velocity and the particle size of the triglyceride, was subsequently investigated 
(chapter 7). The glyceroltripalmitate microparticles used did not degrade completely within 
the duration of 8 weeks of the in vivo experiment, but a tendency of decreasing particle size 
was observed. Since the two glyceroltripalmitate powder groups, which were smaller than the 
microparticles, were completely degraded within 42 days, this hypothesis could be 
demonstrated in at least one example. Additionally, the influence of the degree of crystallinity 
of the triglyceride powder on its in vivo erosion was investigated in this study and shown to 
have a negligible effect. 
In further experiments, the application of triglyceride matrices within programmable 
implants to achieve controlled prolonged release was investigated (chapter 8). These devices 
were developed by Vogelhuber et al. [39] and comprise a drug-loaded core embedded into a 
mantle consisting of a bulk eroding polymer, which inhibits release from the system until it 
starts to erode. Afterwards, the drug is released in a pulsatile manner from the devices 
described by Vogelhuber et al. [39], due to the polyanhydride, which is used as the core 
material. With the intent of prolonging the release, glyceroltrilaurate (C12), 
glyceroltrimyristate (C14), glyceroltripalmitate (C16), glyceroltristearate (C18) and 
cholesterol were investigated as core materials. The use of the triglycerides as matrix 
materials for the preparation of the drug-loaded core led to controlled release over several 
months from the newly developed programmable implants. Cholesterol cores resulted in a 
pulsatile release. In these experiments, the manufacturing procedure was adapted to and 
optimized for the triglycerides. By varying the polymeric mantle material, the onset of release 
was varied from 8 to 83 days. Finally, mathematical modeling using convolution was proven 
to yield sensible results for the prediction of release profiles from programmable implants 
when release of the respective drug from the core material itself is known (chapter 8). This 
facilitates the design of programmable implants with any desired release profile. 
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2. Conclusions 
In conclusion, important steps towards the design and understanding of triglyceride 
matrices as controlled release devices were taken and safety of the biomaterial for parenteral 
application was proved. Crucial parameters for the manufacture of triglyceride implants were 
identified and the extension of their influence on the resulting release profiles was cleared up. 
Basic characteristics of triglycerides as biomaterials for controlled release were elaborated 
and release mechanisms were identified using glyceroltripalmitate as representative material. 
Thus, the design of controlled release devices from this material, having desired release 
profiles was facilitated. Furthermore, biocompatibility, one of the most important 
characteristics for the suitability of a material to serve as matrix material for parenteral 
administered devices, was shown for glyceroltripalmitate and cholesterol. Essential 
knowledge on the in vivo erosion of triglycerides and the potential parameters that influence 
the degradation was acquired. 
In additional experiments, protocols for the extraction of insulin and somatostatin from 
glyceroltripalmitate matrices for the determination of the residue content and for further 
experiments on protein and peptide stability within the triglyceride matrix were established. 
High extraction yields and good reproducibility were achieved. 
Finally, release from programmable implants was shifted from pulsatile to controlled 
prolonged release. The preparation procedure was optimized and reproducible times for the 
inhibition of release by the polymeric mantle were achieved. Concomitantly, using 
convolution for mathematical modeling a correlation of the resulting release profiles from 
programmable implants with the release from the core materials themselves was shown. 
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List of Abbreviations 
AIDS acquired immunodeficiency syndrome 
ANOVA analysis of variance 
BBB blood-brain barrier 
BGS Beta Gamma Service 
DMPC dimyristoyl-phosphatidyl-choline 
DPPC dipalmitoyl-phosphatidyl-choline 
DSC differential scanning calorimetry 
DSPC distearoyl-phosphatidyl-choline 
Em. emission 
EVAc Ethylvinylacetate copolymer 
Ex. extinction 
GFC gel filtration chromatography 
HCl hydrochloric acid 
HIV human immunodeficiency virus 
HPLC high performance liquid chromatography 
i.m. intramuscularly 
i.v. intravenously 
LC/MS liquid chromatography coupled with mass spectrometry 
Mw weight average molecular weight 
m/z mass-per-charge 
NMRI Naval Medical Research Institute 
pBMA poly(butylmethacrylate) 
pCPP-SA poly(bis(p-carboxyphenoxy)propane) - sebacic acid 
PDMS poly(dimethylsiloxane) 
PEG poly(ethylene glycol) 
PES polyester 
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Ph. Eur. Pharmacopoea Europaea 
PLA poly(D,L-lactic acid) 
PLGA poly(D,L-lactic-co-glycolic acid) 
PMMA poly(methylmethacrylate) 
PTFE polytetrafluor-ethylen 
s.c. subcutaneously 
SD standard deviation 
SEM scanning electron microscopy 
TFA trifluoroacetic acid 
Tg glass transition temperature 
THF tetrahydrofurane 
% (w/w) percent, weight per weight 
WAXD wide angle X-ray diffractometry 
WHO World health organisation 
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